145 results on '"Sanchez ML"'
Search Results
2. Global consortium for the classification of fungi and fungus-like taxa
- Author
-
Hyde, KD, Abdel-Wahab, MA, Abdollahzadeh, J, Abeywickrama, PD, Absalan, S, Afshari, N, Ainsworth, AM, Akulov, OY, Aleoshin, VV, Al-Sadi, AM, Alvarado, P, Alves, A, Alves-Silva, G, Amalfi, M, Amira, Y, Amuhenage, TB, Anderson, J, Antonín, V, Aouali, S, Aptroot, A, Apurillo, CCS, Araújo, JPM, Ariyawansa, HA, Armand, A, Arumugam, E, Asghari, R, Assis, DMA, Atienza, V, Avasthi, S, Azevedo, E, Bahkali, AH, Bakhshi, M, Banihashemi, Z, Bao, DF, Baral, HO, Barata, M, Barbosa, F, Barbosa, RN, Barreto, RW, Baschien, C, Belamesiatseva, DB, Bennett Reuel, M, Bera, I, Bezerra, JDP, Bezerra, JL, Bhat, DJ, Bhunjun, CS, Bianchinotti, MV, Błaszkowski, J, Blondelle, A, Boekhout, T, Bonito, G, Boonmee, S, Boonyuen, N, Bregant, C, Buchanan, P, Bundhun, D, Burgaud, G, Burgess, T, Buyck, B, Cabarroi-Hernández, M, Cáceres, MES, Caeiro, MF, Cai, L, Cai, MF, Calabon, MS, Calaça, FJS, Callalli, M, Cano-Lira, JF, Cantillo, T, Cao, B, Carlavilla, JR, Carvalho, A, Castañeda-Ruiz, RF, Castlebury, L, Castro-Jauregui, O, Catania, MDV, Cavalcanti, LH, Cazabonne, J, Cedeño-Sanchez, ML, Chaharmiri-Dokhaharani, S, Chaiwan, N, Chakraborty, N, Chaverri, P, Cheewangkoon, R, Chen, C, Chen, CY, Chen, KH, Chen, J, Chen, Q, Chen, WH, Chen, YP, Chethana, KWT, Coleine, C, Condé, TO, Corazon-Guivin, MA, Cortés-Pérez, A, Costa-Rezende, DH, Courtecuisse, R, Crouch, JA, Crous, PW, Cui, BK, Cui, YY, da Silva, DKA, da Silva, GA, da Silva, IR, da Silva, RMF, da Silva Santos, AC, Dai, DQ, Dai, YC, Damm, U, Darmostuk, V, Daroodi, Zoha, Das, K, Davoodian, N, Davydov, EA, Dayarathne, MC, Decock, C, de Groot, MD, De Kesel, A, dela Cruz, TEE, De Lange, R, Delgado, G, Denchev, CM, Denchev, TT, de Oliveira, NT, de Silva, NI, de Souza, FA, Dentinger, B, Devadatha, B, Dianese, JC, Dima, B, Diniz, AG, Dissanayake, AJ, Dissanayake, LS, Doğan, HH, Doilom, M, Dolatabadi, S, Dong, W, Dong, ZY, Dos Santos, LA, Drechsler-Santos, ER, Du, TY, Dubey, MK, Dutta, AK, Egidi, E, Elliott, TF, Elshahed, MS, Erdoğdu, M, Ertz, D, Etayo, J, Evans, HC, Fan, XL, Fan, YG, Fedosova, AG, Fell, J, Fernandes, I, Firmino, AL, Fiuza, PO, Flakus, A, Fragoso de Souza, CA, Frisvad, JC, Fryar, SC, Gabaldón, T, Gajanayake, AJ, Galindo, LJ, Gannibal, PB, García, D, García-Sandoval, SR, Garrido-Benavent, I, Garzoli, L, Gautam, AK, Ge, ZW, Gené, DJ, Gentekaki, E, Ghobad-Nejhad, M, Giachini, AJ, Gibertoni, TB, Góes-Neto, A, Gomdola, D, Gomes de Farias, AR, Gorjón, SP, Goto, BT, Granados-Montero, MM, Griffith, GW, Groenewald, JZ, Groenewald, M, Grossart, HP, Gueidan, C, Gunarathne, A, Gunaseelan, S, Gusmão, LFP, Gutierrez, AC, Guzmán-Dávalos, L, Haelewaters, D, Halling, R, Han, YF, Hapuarachchi, KK, Harder, CB, Harrington, TC, Hattori, T, He, MQ, He, S, He, SH, Healy, R, Herández-Restrepo, M, Heredia, G, Hodge, KT, Holgado-Rojas, M, Hongsanan, S, Horak, E, Hosoya, T, Houbraken, J, Huang, SK, Huanraluek, N, Hur, JS, Hurdeal, VG, Hustad, VP, Iotti, M, Iturriaga, T, Jafar, E, Janik, P, Jayalal, RGU, Jayasiri, SC, Jayawardena, RS, Jeewon, R, Jerônimo, GH, Jesus, AL, Jin, J, Johnston, PR, Jones, EBG, Joshi, Y, Justo, A, Kaishian, P, Kakishima, M, Kaliyaperumal, M, Kang, GP, Kang, JC, Karimi, O, Karpov, SA, Karunarathna, SC, Kaufmann, M, Kemler, M, Kezo, K, Khyaju, S, Kirchmair, M, Kirk, PM, Kitaura, MJ, Klawonn, I, Kolarik, M, Kong, A, Kuhar, F, Kukwa, M, Kumar, S, Kušan, I, Lado, C, Larsson, KH, Latha, KPD, Lee, HB, Leonardi, M, Leontyev, DL, Lestari, AS, Li, CJY, Li, DW, Li, H, Li, HY, Li, L, Li, QR, Li, WL, Li, Y, Li, YC, Liao, CF, Liimatainen, K, Lim, YW, Lin, CG, Linaldeddu, BT, Linde, CC, Linn, MM, Liu, F, Liu, JK, Liu, NG, Liu, S, Liu, SL, Liu, XF, Liu, XY, Liu, XZ, Liu, ZB, Lu, L, Lu, YZ, Luangharn, T, Luangsaard, JJ, Lumbsch, HT, Lumyong, S, Luo, L, Luo, M, Luo, ZL, Ma, J, Machado, AR, Madagammana, AD, Madrid, H, Magurno, F, Magyar, D, Mahadevan, N, Maharachchikumbura, SSN, Maimaiti, Y, Malosso, E, Manamgoda, DS, Manawasinghe, IS, Mapook, A, Marasinghe, DS, Mardones, M, Marin-Felix, Y, Márquez, R, Masigol, H, Matočec, N, May, T, McKenzie, EHC, Meiras-Ottoni, A, Melo, RFR, Mendes, ARL, Mendieta, S, Meng, QF, Menkis, A, Menolli Jr, N, Mešić, A, Meza Calvo, JG, Mikhailov, KV, Miller, SL, Moncada, B, Moncalvo, JM, Monteiro, JS, Monteiro, M, Mora-Montes, HM, Moreau, PA, Mueller, GM, Mukhopadyay, S, Murugadoss, R, Nagy, LG, Najafiniya, M, Nanayakkara, CM, Nascimento, CC, Nei, Y, Neves, MA, Neuhauser, S, Niego, AGT, Nilsson, RH, Niskanen, T, Niveiro, N, Noorabadi, MT, Noordeloos, (Machiel E.), Norphanphoun, C, Nuñez Otaño, NB, O’Donnell, RP, Oehl, F, Olariaga, I, Orlando, FP, Pang, KL, Papp, V, Pawłowska, J, Peintner, U, Pem, D, Pereira, OL, Perera, RH, Perez-Moreno, J, Perez-Ortega, S, Péter, G, Phillips, AJL, Phonemany, M, Phukhamsakda, C, Phutthacharoen, K, Piepenbring, M, Pires-Zottarelli, CLA, Poinar, G, Pošta, A, Prieto, M, Promputtha, I, Quandt, CA, Radek, R, Rahnama, K, Raj, KNA, Rajeshkumar, KC, Rämä, T, Rambold, G, Ramírez-Cruz, V, Rasconi, S, Rathnayaka, AR, Raza, M, Ren, GC, Robledo, GL, Rodriguez-Flakus, P, Ronikier, A, Rossi, W, Ryberg, M, Ryvarden, LR, Salvador‑Montoya, CA, Samant, B, Samarakoon, BC, Samarakoon, MC, Sánchez-Castro, I, Sánchez-García, M, Sandoval-Denis, M, Santiago, ALCMA, Santamaria, B, Santos, ACS, Sarma, VV, Savchenko, A, Savchenko, K, Saxena, RK, Scholler, M, Schoutteten, N, Seifollahi, E, Selbmann, L, Selcuk, F, Senanayake, IC, Shabashova, TG, Shen, HW, Shen, YM, SilvaFilho, AGS, Simmons, DR, Singh, R, Sir, EB, Song, Chang-Ge, Souza-Motta, CM, Sruthi, OP, Stadler, M, Stchigel, AM, Stemler, J, Stephenson, SL, Strassert, JFH, Su, HL, Su, L, Suetrong, S, Sulistyo, B, Sun, YF, Sun, YR, Svantesson, Sten, Sysouphanthong, P, Takamatsu, S, Tan, TH, Tanaka, K, Tang, AMC, Tang, X, Tanney, JB, Tavakol, NM, Taylor, JE, Taylor, PWJ, Tedersoo, L, Tennakoon, DS, Thamodini, GK, Thines, M, Thiyagaraja, V, Thongklang, N, Tiago, PV, Tian, Q, Tian, WH, Tibell, L, Tibell, S, Tibpromma, S, Tkalčec, Z, Tomšovský, M, Toome-Heller, M, Torruella, G, Tsurykau, A, Udayanga, D, Ulukapi, M, Untereiner, WA, Uzunov, BA, Valle, LG, Van Caenegem, W, Van den Wyngaert, S, Van Vooren, N, Velez, P, Verma, RK, Vieira, LC, Vieira, WAS, Vizzini, A, Walker, A, Walker, AK, Wanasinghe, DN, Wang, CG, Wang, K, Wang, SX, Wang, XY, Wang, Y, Wannasawang, N, Wartchow, F, Wei, DP, Wei, XL, White, JF, Wijayawardene, NN, Wijesinghe, SN, Wijesundara, DSA, Wisitrassameewong, K, Worthy, FR, Wu, F, Wu, G, Wu, HX, Wu, N, Wu, WP, Wurzbacher, C, Xiao, YP, Xiong, YR, Xu, LJ, Xu, R, Xu, RF, Xu, RJ, Xu, TM, Yakovchenko, L, Yan, JY, Yang, H, Yang, J, Yang, ZL, Yang, YH, Yapa, N, Yasanthika, E, Youssef, NH, Yu, FM, Yu, Q, Yu, YX, Yu, ZF, Yuan, HS, Yuan, Y, Yurkov, A, Zafari, D, Zamora, JC, Zare, R, Zeng, M, Zeng, NK, Zeng, XY, Zhang, F, Zhang, H, Zhang, JF, Zhang, JY, Zhang, QY, Zhang, SN, Zhang, W, Zhang, Y, Zhang, YX, Zhao, CL, Zhao, H, Zhao, Q, Zhao, RL, Zhou, LW, Zhou, M, Zhurbenko, MP, Zin, HH, Zucconi, L, Hyde, KD, Abdel-Wahab, MA, Abdollahzadeh, J, Abeywickrama, PD, Absalan, S, Afshari, N, Ainsworth, AM, Akulov, OY, Aleoshin, VV, Al-Sadi, AM, Alvarado, P, Alves, A, Alves-Silva, G, Amalfi, M, Amira, Y, Amuhenage, TB, Anderson, J, Antonín, V, Aouali, S, Aptroot, A, Apurillo, CCS, Araújo, JPM, Ariyawansa, HA, Armand, A, Arumugam, E, Asghari, R, Assis, DMA, Atienza, V, Avasthi, S, Azevedo, E, Bahkali, AH, Bakhshi, M, Banihashemi, Z, Bao, DF, Baral, HO, Barata, M, Barbosa, F, Barbosa, RN, Barreto, RW, Baschien, C, Belamesiatseva, DB, Bennett Reuel, M, Bera, I, Bezerra, JDP, Bezerra, JL, Bhat, DJ, Bhunjun, CS, Bianchinotti, MV, Błaszkowski, J, Blondelle, A, Boekhout, T, Bonito, G, Boonmee, S, Boonyuen, N, Bregant, C, Buchanan, P, Bundhun, D, Burgaud, G, Burgess, T, Buyck, B, Cabarroi-Hernández, M, Cáceres, MES, Caeiro, MF, Cai, L, Cai, MF, Calabon, MS, Calaça, FJS, Callalli, M, Cano-Lira, JF, Cantillo, T, Cao, B, Carlavilla, JR, Carvalho, A, Castañeda-Ruiz, RF, Castlebury, L, Castro-Jauregui, O, Catania, MDV, Cavalcanti, LH, Cazabonne, J, Cedeño-Sanchez, ML, Chaharmiri-Dokhaharani, S, Chaiwan, N, Chakraborty, N, Chaverri, P, Cheewangkoon, R, Chen, C, Chen, CY, Chen, KH, Chen, J, Chen, Q, Chen, WH, Chen, YP, Chethana, KWT, Coleine, C, Condé, TO, Corazon-Guivin, MA, Cortés-Pérez, A, Costa-Rezende, DH, Courtecuisse, R, Crouch, JA, Crous, PW, Cui, BK, Cui, YY, da Silva, DKA, da Silva, GA, da Silva, IR, da Silva, RMF, da Silva Santos, AC, Dai, DQ, Dai, YC, Damm, U, Darmostuk, V, Daroodi, Zoha, Das, K, Davoodian, N, Davydov, EA, Dayarathne, MC, Decock, C, de Groot, MD, De Kesel, A, dela Cruz, TEE, De Lange, R, Delgado, G, Denchev, CM, Denchev, TT, de Oliveira, NT, de Silva, NI, de Souza, FA, Dentinger, B, Devadatha, B, Dianese, JC, Dima, B, Diniz, AG, Dissanayake, AJ, Dissanayake, LS, Doğan, HH, Doilom, M, Dolatabadi, S, Dong, W, Dong, ZY, Dos Santos, LA, Drechsler-Santos, ER, Du, TY, Dubey, MK, Dutta, AK, Egidi, E, Elliott, TF, Elshahed, MS, Erdoğdu, M, Ertz, D, Etayo, J, Evans, HC, Fan, XL, Fan, YG, Fedosova, AG, Fell, J, Fernandes, I, Firmino, AL, Fiuza, PO, Flakus, A, Fragoso de Souza, CA, Frisvad, JC, Fryar, SC, Gabaldón, T, Gajanayake, AJ, Galindo, LJ, Gannibal, PB, García, D, García-Sandoval, SR, Garrido-Benavent, I, Garzoli, L, Gautam, AK, Ge, ZW, Gené, DJ, Gentekaki, E, Ghobad-Nejhad, M, Giachini, AJ, Gibertoni, TB, Góes-Neto, A, Gomdola, D, Gomes de Farias, AR, Gorjón, SP, Goto, BT, Granados-Montero, MM, Griffith, GW, Groenewald, JZ, Groenewald, M, Grossart, HP, Gueidan, C, Gunarathne, A, Gunaseelan, S, Gusmão, LFP, Gutierrez, AC, Guzmán-Dávalos, L, Haelewaters, D, Halling, R, Han, YF, Hapuarachchi, KK, Harder, CB, Harrington, TC, Hattori, T, He, MQ, He, S, He, SH, Healy, R, Herández-Restrepo, M, Heredia, G, Hodge, KT, Holgado-Rojas, M, Hongsanan, S, Horak, E, Hosoya, T, Houbraken, J, Huang, SK, Huanraluek, N, Hur, JS, Hurdeal, VG, Hustad, VP, Iotti, M, Iturriaga, T, Jafar, E, Janik, P, Jayalal, RGU, Jayasiri, SC, Jayawardena, RS, Jeewon, R, Jerônimo, GH, Jesus, AL, Jin, J, Johnston, PR, Jones, EBG, Joshi, Y, Justo, A, Kaishian, P, Kakishima, M, Kaliyaperumal, M, Kang, GP, Kang, JC, Karimi, O, Karpov, SA, Karunarathna, SC, Kaufmann, M, Kemler, M, Kezo, K, Khyaju, S, Kirchmair, M, Kirk, PM, Kitaura, MJ, Klawonn, I, Kolarik, M, Kong, A, Kuhar, F, Kukwa, M, Kumar, S, Kušan, I, Lado, C, Larsson, KH, Latha, KPD, Lee, HB, Leonardi, M, Leontyev, DL, Lestari, AS, Li, CJY, Li, DW, Li, H, Li, HY, Li, L, Li, QR, Li, WL, Li, Y, Li, YC, Liao, CF, Liimatainen, K, Lim, YW, Lin, CG, Linaldeddu, BT, Linde, CC, Linn, MM, Liu, F, Liu, JK, Liu, NG, Liu, S, Liu, SL, Liu, XF, Liu, XY, Liu, XZ, Liu, ZB, Lu, L, Lu, YZ, Luangharn, T, Luangsaard, JJ, Lumbsch, HT, Lumyong, S, Luo, L, Luo, M, Luo, ZL, Ma, J, Machado, AR, Madagammana, AD, Madrid, H, Magurno, F, Magyar, D, Mahadevan, N, Maharachchikumbura, SSN, Maimaiti, Y, Malosso, E, Manamgoda, DS, Manawasinghe, IS, Mapook, A, Marasinghe, DS, Mardones, M, Marin-Felix, Y, Márquez, R, Masigol, H, Matočec, N, May, T, McKenzie, EHC, Meiras-Ottoni, A, Melo, RFR, Mendes, ARL, Mendieta, S, Meng, QF, Menkis, A, Menolli Jr, N, Mešić, A, Meza Calvo, JG, Mikhailov, KV, Miller, SL, Moncada, B, Moncalvo, JM, Monteiro, JS, Monteiro, M, Mora-Montes, HM, Moreau, PA, Mueller, GM, Mukhopadyay, S, Murugadoss, R, Nagy, LG, Najafiniya, M, Nanayakkara, CM, Nascimento, CC, Nei, Y, Neves, MA, Neuhauser, S, Niego, AGT, Nilsson, RH, Niskanen, T, Niveiro, N, Noorabadi, MT, Noordeloos, (Machiel E.), Norphanphoun, C, Nuñez Otaño, NB, O’Donnell, RP, Oehl, F, Olariaga, I, Orlando, FP, Pang, KL, Papp, V, Pawłowska, J, Peintner, U, Pem, D, Pereira, OL, Perera, RH, Perez-Moreno, J, Perez-Ortega, S, Péter, G, Phillips, AJL, Phonemany, M, Phukhamsakda, C, Phutthacharoen, K, Piepenbring, M, Pires-Zottarelli, CLA, Poinar, G, Pošta, A, Prieto, M, Promputtha, I, Quandt, CA, Radek, R, Rahnama, K, Raj, KNA, Rajeshkumar, KC, Rämä, T, Rambold, G, Ramírez-Cruz, V, Rasconi, S, Rathnayaka, AR, Raza, M, Ren, GC, Robledo, GL, Rodriguez-Flakus, P, Ronikier, A, Rossi, W, Ryberg, M, Ryvarden, LR, Salvador‑Montoya, CA, Samant, B, Samarakoon, BC, Samarakoon, MC, Sánchez-Castro, I, Sánchez-García, M, Sandoval-Denis, M, Santiago, ALCMA, Santamaria, B, Santos, ACS, Sarma, VV, Savchenko, A, Savchenko, K, Saxena, RK, Scholler, M, Schoutteten, N, Seifollahi, E, Selbmann, L, Selcuk, F, Senanayake, IC, Shabashova, TG, Shen, HW, Shen, YM, SilvaFilho, AGS, Simmons, DR, Singh, R, Sir, EB, Song, Chang-Ge, Souza-Motta, CM, Sruthi, OP, Stadler, M, Stchigel, AM, Stemler, J, Stephenson, SL, Strassert, JFH, Su, HL, Su, L, Suetrong, S, Sulistyo, B, Sun, YF, Sun, YR, Svantesson, Sten, Sysouphanthong, P, Takamatsu, S, Tan, TH, Tanaka, K, Tang, AMC, Tang, X, Tanney, JB, Tavakol, NM, Taylor, JE, Taylor, PWJ, Tedersoo, L, Tennakoon, DS, Thamodini, GK, Thines, M, Thiyagaraja, V, Thongklang, N, Tiago, PV, Tian, Q, Tian, WH, Tibell, L, Tibell, S, Tibpromma, S, Tkalčec, Z, Tomšovský, M, Toome-Heller, M, Torruella, G, Tsurykau, A, Udayanga, D, Ulukapi, M, Untereiner, WA, Uzunov, BA, Valle, LG, Van Caenegem, W, Van den Wyngaert, S, Van Vooren, N, Velez, P, Verma, RK, Vieira, LC, Vieira, WAS, Vizzini, A, Walker, A, Walker, AK, Wanasinghe, DN, Wang, CG, Wang, K, Wang, SX, Wang, XY, Wang, Y, Wannasawang, N, Wartchow, F, Wei, DP, Wei, XL, White, JF, Wijayawardene, NN, Wijesinghe, SN, Wijesundara, DSA, Wisitrassameewong, K, Worthy, FR, Wu, F, Wu, G, Wu, HX, Wu, N, Wu, WP, Wurzbacher, C, Xiao, YP, Xiong, YR, Xu, LJ, Xu, R, Xu, RF, Xu, RJ, Xu, TM, Yakovchenko, L, Yan, JY, Yang, H, Yang, J, Yang, ZL, Yang, YH, Yapa, N, Yasanthika, E, Youssef, NH, Yu, FM, Yu, Q, Yu, YX, Yu, ZF, Yuan, HS, Yuan, Y, Yurkov, A, Zafari, D, Zamora, JC, Zare, R, Zeng, M, Zeng, NK, Zeng, XY, Zhang, F, Zhang, H, Zhang, JF, Zhang, JY, Zhang, QY, Zhang, SN, Zhang, W, Zhang, Y, Zhang, YX, Zhao, CL, Zhao, H, Zhao, Q, Zhao, RL, Zhou, LW, Zhou, M, Zhurbenko, MP, Zin, HH, and Zucconi, L
- Abstract
The Global Consortium for the Classification of Fungi and fungus-like taxa is an international initiative of more than 550 mycologists to develop an electronic structure for the classification of these organisms. The members of the Consortium originate from 55 countries/regions worldwide, from a wide range of disciplines, and include senior, mid-career and early-career mycologists and plant pathologists. The Consortium will publish a biannual update of the Outline of Fungi and funguslike taxa, to act as an international scheme for other scientists. Notes on all newly published taxa at or above the level of species will be prepared and published online on the Outline of Fungi website (https://www.outlineoffungi.org/), and these will be finally published in the biannual edition of the Outline of Fungi and fungus-like taxa. Comments on recent important taxonomic opinions on controversial topics will be included in the biannual outline. For example, ‘to promote a more stable taxonomy in Fusarium given the divergences over its generic delimitation’, or ‘are there too many genera in the Boletales?’ and even more importantly, ‘what should be done with the tremendously diverse ‘dark fungal taxa?’ There are undeniable differences in mycologists’ perceptions and opinions regarding species classification as well as the establishment of new species. Given the pluralistic nature of fungal taxonomy and its implications for species concepts and the nature of species, this consortium aims to provide a platform to better refine and stabilise fungal classification, taking into consideration views from different parties. In the future, a confidential voting system will be set up to gauge the opinions of all mycologists in the Consortium on important topics. The results of such surveys will be presented to the International Commission on the Taxonomy of Fungi (ICTF) and the Nomenclature Committee for Fungi (NCF) with opinions and percentages of votes for and against. Criticisms based o
- Published
- 2023
- Full Text
- View/download PDF
3. Survival Rate of CAD–CAM Endocrowns Performed by Undergraduate Students
- Author
-
Munoz-Sanchez, Ml, Bessadet, M, Lance, C, Bonnet, G, Veyrune, Jl, Nicolas, E, Hennequin, Martine, Decerle, N, Centre de Recherche en Odontologie Clinique (CROC), and Université Clermont Auvergne (UCA)
- Subjects
Cohort Studies ,Survival Rate ,Tooth, Nonvital ,Crowns ,Dental Prosthesis Design ,[SDV]Life Sciences [q-bio] ,Computer-Aided Design ,Humans ,Students ,General Dentistry - Abstract
SUMMARY Objectives: This study aimed to evaluate the success of computer-aided design–computer-aided manufacturing (CAD–CAM) endocrown restorations of endodontically treated teeth (ETT) performed by supervised undergraduate students. The study also intended to identify possible factors that may lead to failures. Methods and Materials: This observational open cohort study was based on clinical data from endocrown restorations performed by residents and undergraduate students in their 4th, 5th, and 6th year from July 2011 to May 2018. The presence of a tooth with an endocrown on the arch was the main criteria used to calculate the survival rate of restored teeth. The quality of the remaining endocrowns was evaluated referring to the FDI criteria. The cases of failure were categorized into either favorable or unfavorable. Results: A total of 343 ETT were restored with endocrowns in 315 patients. Among them, 199 patients encompassing 225 endocrowns were followed during a 56 ± 26 month period. The survival rate of restored teeth was found to be 81.8%, the estimated Kaplan–Meier survival rate being 71.8% at 9 years. Among the 41 failed cases, 32 were favorable (debonding and/or ceramic fractures) and 9 were unfavorable. Conclusion: Endocrown restorations of posterior ETT using CAD–CAM technologies could be carried out by undergraduates with a low risk of failure. Teacher supervision could be reinforced, covering all steps of each endocrown procedure in order to avoid failures due to insufficient thickness or loss of retention.
- Published
- 2021
- Full Text
- View/download PDF
4. End-of-life care for patients hospitalised in internal medicine departments
- Author
-
Diez-Manglano, J, Perez, SIDI, Gomez, MR, Formiga, F, Munoz, LAS, Herrero, JC, Vales, EC, Bonafonte, OHT, Perez, MM, Garcia, LFD, Maroto, IV, Losada, CO, Escobar, PG, Perez, CD, Granado, JC, Font, RMG, Lorente, FJJ, Vazquez, GP, Exposito, ABF, Gonzalez, MLA, Antinolo, FG, Molina, AG, Hernandez, MG, Garcia, MG, Leon, LB, Rivas, LM, Mariscal, MR, Aguirre, NG, Garcia, MPG, Algora, IM, Castel, MCB, Laiglesia, FR, Tello, EB, Garcia, JLC, Fernandez, NG, Camera, L, Gauna, C, Requejo, PA, Gutierrez, RM, Regueiro, RF, Vidal, MTS, Mejido, JA, Carus, EG, Rodriguez, CEC, Garcia, PM, Olivares, SR, Barcelo, MIF, Arencibia, CG, Vilamajo, RR, Prieto, MJM, Becerra, CG, Plata, SPAM, Chocarro, RP, Gutierrez, CD, Alvarez, FE, Balbuena, SP, Galindo, RR, Siles, MMC, Lopez, AC, Lobo, CS, Vinas, MMC, Uriel, MAC, Dominguez, JG, Gonzalez, FM, Lazaro, JMM, Gamboa, JM, Galdeano, MR, Gimenez, JC, Farre, JRB, Aragon, RN, Toran, FM, Bare, J, Farre, EG, Minana, AL, Sarabia, DM, Perez, R, Fernandez, DAI, Fernandez, JF, Salomo, AC, Qanneta, R, Ortega, MVP, Diaz, CE, Pintado, YM, Cors, MG, Rivas, MCA, Albin, DD, Morera, JR, Alvaro, NG, Parodi, AT, Sanchez, ML, Acebal, CD, Garcia, JZ, Claveras, LB, Cabanes, JM, Lazaro, IS, Romero, JB, Lopez-Alegria, LN, Lorido, JCA, Vizcaya, AML, Rodriguez, CM, Fernandez, SP, Sanchez, PS, Jimenez-Beatty, MD, Vazquez, LG, Hernando, AB, Anglada, MIG, Lorenzo, VMG, Martin, AP, Melcon, GG, Antunez, MG, Simon, MAQ, Gil, FG, Martinez, MA, Aragoneses, LM, Parra, JC, Perez, MDR, Garcia, JC, Cuesta, FL, Abad, MES, Ortega, MF, Martinez, GL, Blanco, AP, Fraile, RR, Litago, EM, Echeverria, AE, Valladares, MP, Serrano, CT, Mas, JV, Suau, OT, Tomas, EG, Rubio, RC, Zaragoza, JMM, Sanchez, PR, Herola, AG, Doblas, PPT, Encinar, JCB, Vela, EC, Carrizo, N, Galvan, VG, Villanueva, BMR, Liano, FP, and Izuel, JMP
- Subjects
Palliative sedation ,End-of-life care ,Do-not-resuscitate order ,Terminal disease ,In-hospital dying - Abstract
Objectives: To describe the care provided at the end of life for patients who die in internal medicine departments. Methods: An observational, cross-sectional, retrospective multicentre, clinical audit study was conducted where each hospital included the first 10 patients who died in the internal medicine department starting on December 1, 2015. We collected demographic and clinical data and information regarding the circumstances and care at the time of death. Results: The study included 1,447 patients with a median age of 84 years. Of these, 1,065 (74.3%) were polypathological, 751 (51.9%) were terminal and 248 (17.1%) had cancer. For the terminal patients, do-not-resuscitate orders were established for 539 (73.3%), and palliative sedation was performed for 422 (57.4%). There was no record as to whether psychological, religious or grief care was provided in 32%, 64.8% and 44.1% of the terminal patients, respectively. The patients with cancer were more often competent to make decisions (54.4% vs. 15.5%; P
- Published
- 2019
5. Systemic effect of continuous treatment with azithromycyn in patients with severe COPD and frequent exacerbations
- Author
-
Sales, EC, Almela, DH, Gonzalezi, YP, Sanchez, ML, Soler, CM, Amigo, P, Tapia, AM, Nunez, MG, Marti, SM, and Perez, SS
- Subjects
Inflammation ,Chronic diseases ,Biomarkers - Published
- 2019
6. Yarrow by Parts: An Ethnobotanical, Pharmacological, and Metabolomics Analysis of One of North America's Most Important Medicinal Plants
- Author
-
Kachura, A, additional, Lee, T, additional, Sanchez, ML, additional, Rhéaume, É, additional, Zaghrini, W, additional, Liu, R, additional, Haddad, PS, additional, Overy, DP, additional, and Harris, CS, additional
- Published
- 2018
- Full Text
- View/download PDF
7. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
- Author
-
Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Civeira, F., Flather, M., Glynn, R. J., Gregoire, J., Jukema, J. W., Karpov, Y., Kastelein, J. J. P., Koenig, W., Lorenzatti, A., Manga, P., Masiukiewicz, U., Miller, M., Mosterd, A., Murin, J., Nicolau, J. C., Nissen, S., Ponikowski, P., Santos, R. D., Schwartz, P. F., Soran, H., White, H., Wright, R. S., Vrablik, M., Yunis, C., Shear, C. L., Tardif, Conde D, J. -C., Colquhoun, D, Missault, L, Grégoire, J, Gao, R, Urina, M, Solar, M, Jensen, Hk, Grobbee, D, Savolainen, M, Schiele, Fn, Montalescot, G, Edes, I, Blake, G, Lotan, C, Maggioni, A, Savonitto, S, Lee, Cw, Leiva Pons JL, Dan, Ga, Cortada, Jb, Mellbin, L, Kahan, T, Noble, S, Hwang, Jj, Sritara, P, Tökgozoğlu, L, Tarasenko, L, Borer, Js, Black, H, Carmena, R, Furie, Kl, Mcmurray, J, Neaton, J, Zannad, F, O’Neill, B, Welty, F, Mcnamara, R, Chun, H, Abbott, Jd, Jacoby, D, Mcpherson, C, Jadbabaie, F, Pinto, D, Mccullough, L, Silverman, Ie, Sansing, Lh, Dearborn-Tomazos, J, Foody, J, Schindler, J, Piazza, G, Chakrabarti, A, Pride, Y, Gelfand, E, Baultrukonis, D, Chaudhuri, S, Frederich, R, Johnson, M, Mridha, K, Powell, C, Wang, E, Wei, C, Anderson, P, Buonanno, M, Epsley, C, Evans, B, Frolova, M, Goetsch, M, Hessinger, D, Ikehara, E, Ivanac, K, Kizko, J, Le, K, McNally-Dufort, C, Morocco, T, Nadkarni, S, Nissen, T, Nye, R, Pak, R, Pence, D, Redifer, P, Schwartz, W, Sattler, C, Schade, R, Sullivan, B, Wegner, J, Alvarez, Ca, Budassi, N, Vogel, Dr, Avaca, H, Conde, Dg, Estol, Cc, Gelersztein, E, Glenny, Ja, Hershson, Ar, Bruno, Rl, Maffei, Le, Soler, Jm, Zaidman, Cj, Carnero, Gs, Colombo, Hr, Jure, Ho, Luquez, Ha, Ramos, Hr, Resk, Jh, Rusculleda, Mm, Ulla, Mr, Caccavo, A, Farias, Ef, Wenetz, Lm, Cabella, Pr, Cuadrado, Ja, Chahin, M, Mackinnon, Ij, Zarandon, Rb, Schmidberg, J, Fernandez, Aa, Montana, O, Codutti, Or, Gorosito, Vm, Maldonado, N, Sala, J, De La Fuente RA, Casabella, Te, Di Gennaro JP, Guerrero, Ra, Alvarez, Ms, Berli, M, Botta, Ce, Montenegro, Ee, Vico, Ml, Begg, A, Lehman, R, Gilfillan, Cp, D'Emden, M, Markovic, Tp, Sullivan, D, Aroney, C, Stranks, Sn, Crimmins, Ds, Arstall, M, Van Gaal, W, Davis, T, Aylward, Pe, Amerena, J, William, M, Proietto, J, Purnell, Pw, Singh, B, Arya, Kw, Dart, Am, Thompson, P, Davis, Sm, Carroll, Pa, De Looze, F, Jayasinghe, R, Bhindi, R, Buysschaert, I, Sarens, T, van de Borne, P, Scott, Bp, Roosen, J, Cools, F, Missault, Lh, Debroye, C, Schoors, Df, Hollanders, G, Schroe, Hh, De Sutter, J, Hermans, K, Carlier, M, van Landegem, P, Verwerft, J, Mulleners, T, Delforge, Md, Soufflet, V, Elegeert, I, Descamps, Os, Janssens, S, Lemmens, Rc, Desfontaines, P, Scheen, A, Heijmans, S, Capiau, L, Vervoort, G, Carlier, Sg, Faes, D, Alzand, B, Keuleers, S, De Wolf, L, Thoeng, J, De Bruyne, L, de Santos MO, Felicio, Js, Areas, Ca, Figueiredo, El, Michalaros, Yl, Neuenschwander, Fc, Reis, G, Saad, Ja, Kormann, Ap, Nascimento, Cv, Precoma, Db, Abib, E Jr, dos Santos FR, Mello, Yg, Saraiva, Jf, Rech, Rl, Cerci, R, Fortes, Ja, Rossi, Pr, de Lima, e Silva FA, Hissa, M, Silva, Rp, de Souza WK, Guimarães Filho FV, Mangili, Oc, de Oliveira Paiva MS, Tumelero, R, Abrantes, Ja, Caramori, Pr, Dutra, Op, Leaes, Pe, Manenti, Er, Polanczyk, Ca, Bandeira, e Farias FA, de Moraes Junior JB, Russo, La, Alves AR Jr, Dracoulakis, Md, Ritt, Le, Saporito, Wf, Herdy, Ah, Maia, Ln, Sternieri, Mv, Ayoub, Jc, Bianco, Ht, da Costa FA, Eliaschewitz, Fg, Fonseca, Fa, Nakandakare, Er, Bonansea, Tc, Castro, Nm, de Barros, e Silva PG, Smith, P, Botelho, Rv, Resende, Es, Barbieri, Ds, Hernandes, Me, Bajaj, H, Beaudry, P, Berlingieri, Jc, Salter, Tj, Ajala, B, Anderson, Tj, Nanji, A, Ross, S, Pandey, S, Desrosiers, D, Gaudet, D, Moran, G, Csanadi, Ma, St-Amour, E, Cusimano, S, Halperin, Fa, Babapulle, M, Vizel, S, Petrella, J, Spence, Jd, Gupta, N, Tellier, G, Bourgeois, R, Gregóire, Jc, Wesson, T, Zadra, R, Twum-Barima, Dy, Cha, Jy, Hartleib, Mc, Bergeron, J, Chouinard, G, Mcpherson, Tp, Searles, G, Peterson, Sr, Mukherjee, A, Lepage, S, Conway, Jr, Kouz, Sm, Dion, D, Pesant, Y, Cheung, Ss, Goldenberg, Rm, Aronson, R, Gupta, Ak, O’Mahoney, M, Pliamm, L, Teitelbaum, I, Hoag, Gn, Nadra, Ij, Yared, Z, Yao, Lc, Nguyen, T, Saunders, Kk, Potthoff, S, Varleta, P, Assef, V, Godoy, Jg, Olivares, C, Roman, O, Vejar, M, Montecinos, H, Pincetti, C, Li, Y, Wang, D, Li, J, Yang, X, Du, Y, Wang, G, Yang, P, Zhang, X, Xu, P, Zhao, Y, Chen, J, Li, S, Li, W, Zhang, L, Zhu, Y, Zhang, Y, Zhou, C, Wang, Y, Liu, F, Ma, Y, Ti, Z, Zeng, X, Zhou, Y, Cui, G, Li, D, Xue, L, Jiang, J, Lian, Y, He, Y, Mendoza, Ja, Bonfanti, Ja, Dada, Fa, Urina-Triana, Ma, Rodriguez, Wr, Sanchez, Ml, Lozno, Hy, Triana, Eh, Arambula, Rm, Rico-Carrillo, Ae, Gallo, Hj, Catano, Js, Jattin, Fg, Plazas, Ja, Gomez, Je, Botero-Lopez, R, Gomez, Ni, Munoz, Cf, Pelaez, Sv, Eraso, Am, Goyes, Ar, Elbl, L, Fiserova, N, Vesely, J, Wasserburger, B, Blaha, V, Vojacek, J, Maskova, P, Hutyra, M, Vrkoc, J, Hala, T, Vodnansky, P, Bocek, P, Cifkova, R, Bufka, V, Ceska, R, Machkova, M, Zidkova, E, Lukac, M, Mikusova, T, Kellnerova, I, Kuchar, L, Ferkl, R, Cech, V, Zemek, S, Monhart, Z, Davidsen, F, Joensen, A, Lihn, As, Rasmussen, Tk, Wiggers, H, Lindgren, Lm, Schmidt, U, Galatius, S, Sillesen, H, Bronnum Schou, J, Thomsen, Kk, Urhammer, S, Jeppensen, J, Schou, M, May, O, Steffensen, R, Nielsen, Wb, Nielesen, T, Jepsen, Jm, Rai, A, Sykulski, R, Andersen, Lt, Rickers, H, Frost, L, Lomholdt, J, Egstrup, K, Wermuth, S, Klausen, L, Lassus, J, Palomaki, A, Khari, J, Tatlisumak, T, Kekki, S, Vanttinen, E, Strandberg, A, Valtonen, M, Sia, Sm, Nerg, O, Puhakka, M, Strand, J, Timonen, M, Levola, J, Arstila, L, Taurio, J, Kantola, I, Suomi, J, Humaloja, K, Askonen, K, Schiele, F, Sibon, I, Zemour, G, Goube, P, Petit, C, Chati, Z, Range, G, Rabahi, F, Rihani, R, Bergerot, C, Roubille, F, Boye, A, Probst, V, Ferrari, E, Cayla, G, Thouvenot, E, Delarche, N, Couffinhal, T, Coisne, D, Paillard, F, Elbaz, M, Decoulx, E, Angoulvant, D, Agraou, B, Caudmont, S, Berrouschot, J, Lauer, B, Schoell, I, Trenk, D, Derwahl, Km, Khariouzov, A, Proepper, F, Stawowy, P, Da Stephan, U, Stoessel, J, Voehringer, Hf, Dorsel, T, Stellbrink, C, Rinke, A, Northroff, J, Bourhaial, H, Stratmann, M, Wetzel, T, Axthelm, C, Guenzel, A, Weigmann, I, Faghih, M, Hagemann, D, Schaefer, A, Weber, D, Luedemann, J, Contzen, C, Kornmann, Mo, Winkelmann, B, Simon, J, Felix, S, Brauer, C, Laufs, U, Schmidt, E, Marten, I, Licka, M, Heisters, J, Appel, Kf, Kleinecke-Pohl, U, Klein, C, von Hodenberg EF, Maus, O, Sigal, H, Taeschner, H, Schwimmbeck, P, Lemke, B, Perings, C, Illies, G, Pfuetzner, A, Salbach, P, Hengstenberg, C, Kohler, A, Mudra, H, Behnke, T, Baar, M, Jeserich, M, Scholz, G, Naudts, I, Voller, H, Herrmann, Hj, von Engelhardt CB, Gerke, S, Pohlmeier, L, Schaufele, T, Woehrle, J, Al-Zoebi, A, Horacek, T, Peterfai, E, Kemeny, V, Lakatos, F, Bod, E, Andrassy, P, Andreka, P, Balo, T, Davidovits, Z, Laszlo, Z, Nagy, K, Papp, A, Somogyi, A, Toldy-Schedel, E, Vertes, A, Voros, P, Paragh, G, Martyin, T, Hajdu, C, Deak, L, Farago, K, Nagy, A, Kirschner, R, Koszegi, Z, Zilahi, Z, Toth, K, Wittmann, I, Bajcsi, D, Reiber, I, Toth, L, Benczur, B, Nagy, L, Sydo, T, Lupkovics, G, Oroszlan, T, Crean, P, Mahon, Ng, Mcadam, B, Macneill, B, Katz, A, Tsalihin, D, Vazan, A, Eitan, A, Lewis, Bs, Gavish, D, Wainstein, J, Mosenzon, O, Mosseri, M, Vishlitzky, V, Atar, S, Nseir, Wb, Brenner, H, Elis, A, Fuchs, S, Shimon, I, Solodky, A, Goldhaber, A, Tanne, D, Knobler, H, Kracoff, Oh, Hussein, O, Auriel, E, Chorin, E, Sharir, T, Bitzur, R, Shechter, M, Antonicelli, R, Franceschini, E, Porcu, M, Sesti, G, Maggiolini, S, Salvioni, A, Filardi, Pp, Trimarco, B, Averna, M, Pasqualini, L, Pirro, M, Pantaleoni, M, Piovaccari, G, Arca, M, Fedele, Francesco, Roncon, L, Anselmi, M, Sganzerla, P, Morocutti, G, Bonora, E, Dimas, Al, Esperon, Ga, Morales-Villegas, E, Isunza, Jm, Beltran, Lg, Molina, Ca, Garcia, Dk, Ruiz, La, Reyna, Ls, De los Rios Ibarra MO, Soto, Jr, Gonzalez-Ortiz, M, Herrera-Marmolejo, M, Ramos, Sa, Ramos-Lopez, Ga, Stobschinski, Ca, Aguilarsalinas, Ca, Alpizar-Salazar, M, Jimenez-Sanchez, M, Sanchez Mijangos JH, Elizondo Moreno ER, Garcia Castillo, A, Garcia Hernandez PA, Gonzalez-Gonzalez, Jg, Riojas Charles CM, Valdez Lopez HG, Nuriulu Escobar PL, Lechuga Martin del Campo, A, Castro Montes BE, Mendez Bucio, A, Rodriguez-Briones, I, Torre Amione, G, Violante Ortiz, R, Luna Ceballos RI, Lopez Rosas, E, Bax, Wa, Alhakim, M, van de Wiel, A, Liem, Ss, Groutars, Rg, Herrman, Jp, Hovingh, Gk, van de Wetering ML, van Royen, N, Groenemeijer, Be, Hoedemaker, G, Schaap, J, Ronner, E, Angun, M, Mairuhu, At, Van Alem AP, Martens, Fm, Heijmeriks, Ja, van Hal JM, Schoofs, Mw, den Hartog FR, Kentgens, S, Post, Jc, Louwerenburg, Jw, van Rossum, P, Viergever, Ep, Donders, Sh, Kamphuisen, Pw, van Beek, E, Nijmeijer, R, Lenderink, T, Schreuder, T, Kuijper, Af, The, Sh, Van het Hof-Wiersma JJ, Tichelaar, P, Westerndorp, I, Breedveld, Rw, Karalis, I, Romer, Tj, Bogaard, K, Van Koningsbruggen, P, Kroon, Aa, Hoogslag, Pa, Rensing, Bj, Cramer, E, Remmen, Jj, Riksen, Np, Bokern, Mj, Cabezas, Mc, Mulder, H, Nierop, Pr, van Kempen WW, Zoet-Nugteren, Sk, van Daele ME, Swart, Hp, van der Zwaan CT, Hermans, Wr, Magro, M, van de Wal RM, Hassink, Rj, Visseren, F, Veenendaal, A, De Nooijer, C, Troquay, Rp, Imholz, Bp, van der Meer, P, Visser, Rp, van Leendert RJ, Gosselink, Ma, Baker, J, Benatar, Jr, Kerr, J, Pryke, Jr, Scott, Rs, Millar-Corte, Gd, Williams, M, Montgomery, B, Venter, Dj, Ternouth, If, Decaigney, Sc, Hart, Hh, Corin, A, Garden, Pi, Sheahan, D, Harding, Sa, Korecki, J, Supronik, J, Styczkiewicz, M, Bijata-Bronisz, R, Rusicka, T, Walczak, M, Krolikowski, Z, Ostrowski, J, Lukaszewicz, M, Przekwas-Jaruchowska, M, Zieba, B, Miekus, P, Orkwiszewska-Nalewajko, A, Piepiorka, M, Kubalski, P, Wychota, K, Blach, E, Ochala, A, Okopien, B, Wronska, D, Janion, M, Czarnecka, D, Kolodziejczyk, J, Konieczynska, M, Landa, K, Mirek-Bryniarska, E, Necki, M, Pasternak, Da, Rozpondek, P, Trebacz, J, Walczewska, J, Sidor, M, Broncel, M, Drozdz, J, Kosmider, M, Saryusz-Wolska, M, Kucharska, D, Opalinska, E, Pijanowski, Z, Wozniak, I, Banaszkiewicz, K, Klecha, A, Horodecki, M, Piskorz-Wapinska, J, Kobielusz-Gembala, I, Kim, Mh, Kim, Dk, Cho, Br, Kim, Ks, Her, Sh, Lee, Sy, Rhee, My, Kim, K, Kang, Wc, Kim, Dh, Cho, Ys, Kim, Sh, Rim, Sj, Tahk, Sj, Jeon, Hk, Yoon, J, Mociran, M, Pop, Cf, Minescu, B, Andrei, Ld, Radoi, M, Calin, A, Ciomag, Rm, Copaci, I, Fruntelata, Ag, Popescu, M, Tivadar, S, Roman, G, Avram, Ri, Mistodie, Cv, Morosanu, M, Popa, Ar, Popescu, Ml, Popoviciu, Ms, Tase, A, Busegeanu, M, Popescu, A, Szilagyi, I, Sitterli-Natea, Cn, Maximov, Dm, Munteanu, M, Negrisanu, Gd, Kuzin, A, Popov, D, Shapovalova, J, Vishneva, E, Shutemova, E, Pasechnik, E, Bogdanov, E, Khasanov, N, Barbarash, Ol, Shangina, Oa, Tarasov, N, Solonev, O, Kosmacheva, E, Chernyatina, Ma, Ginzburg, M, Blokhin, A, Bulanova, N, Drapkina, Om, Gordeev, Ig, Libov, Ia, Lomakin, N, Panchenko, E, Shogenov, Zs, Zateyshchikov, D, Klein, G, Motylev, I, Belenkiy, Di, Demin, A, Nikolaev, Ky, Oleynikov, V, Zrazhevskiy, K, Katelnitskiy, I, Khaisheva, L, Aksentiev, S, Nedoshivin, A, Popova, Vb, Agafina, As, Ballyuzek, M, Baranova, E, Burova, N, Eryshev, S, Filippov, A, Goloshchekin, Bm, Konstantinov, V, Kostenko, Va, Simanenkov, Vi, Volkova, A, Duplyakov, D, Reshetko, O, Shvarts, Y, Kuznetsov, Va, Samoylova, Yg, Tolkacheva, V, Shalaev, Sv, Khokhlov, Al, Malygin, A, Shilkina, Np, Yakusevich, Vv, Margoczy, R, Zubek, V, Dzupina, A, Dubrava, J, Dulkova, K, Fabryova, L, Gaspar, L, Kamensky, G, Kokles, M, Raslova, K, Soosova, I, Stevlik, J, Strbova, J, Sumbal, J, Uhliar, R, Micik, J, Truban, J, Fedacko, J, Pastrnakova, E, Pella, D, Fazekas, F, Ambrovicova, V, Kycina, P, Martinka, E, Nociar, J, Belicova, M, Banik, M, Kanderkova, D, Hranai, M, Duris, T, Krahulec, B, Benacka, J, Vinanska, D, Roskova, E, Skripova, D, Macek, V, Vohnout, B, Buganova, I, Engelbrecht, Jm, Pretorius, Mm, Ebrahim, Io, Bayat, J, Ganesh, S, Ranjith, N, Coetzer, Tf, Jacovides, A, Distiller, La, Hellig, Fs, Engelbrecht, Iv, Mahomed, Aa, Blignault, Sc, Burgess, Lj, Kotze, Hj, van Nieuwenhuizen, E, Musungaie, Db, Emanuel, S, van der Walt, E, Pretorius, Ce, Roos, Js, Roux, Sm, Badat, Ae, Fouche, L, Vahed, Ya, Jansen van Resburg, D, van Zyl LJ, Soto Gonzalez, A, Diaz, Jl, Segura, T, Botella Serrano, M, Botas Rodrigues, J, Molto-Jorda, Jm, Dominguez Escribano JR, Sogorb Garri, F, Blanco Coronado JL, Gaztambide Saenz MS, Brotons Cuixart, C, Bruguera Cortada, J, Garcia-Moll Marimon, X, Gonzalbez Morgaez JD, Maisterra Santos, O, Roquer Gonzalez, J, Sobrino-Martinez, J, Chueca Fernandez JE, Narejos, S, Suarez Garcia, S, Perez Martinez, P, Figueras Camos, R, Medrano Martinez, V, Bellido Guerrero, D, Martinez Deben, F, Vila Belmonte, A, Mediavilla Garcia JD, Romero Hinojosa JA, Martorell Mateu, E, Cequier Fillat AR, Pinto Sala, X, Adroer Martori, R, Bueno Diez, M, Lopez Cano, C, Worner Diz, F, Gonzalez Juanatey, C, Alvarez-Sala Walther LA, De Dios Garcia Diaz, J, Garcia Puig, J, Jodar Gimeno, E, Plaza Perez, I, Suarez-Fernandez, C, Tunon, J, Zamorano Gomez JL, Brito Sanfiel MA, Escudier Villa JM, de Mora Martin, M, Dominguez Lopez, M, Hernandez Garcia JM, Tinahones Madueno FJ, Perez Paredes, M, Aracil Villar, J, Barreda Gonzalez MJ, Ripoll Vera TV, Tofe Povedano, S, Sanchez Alvarez, J, Martinez Via, L, Robles Iniesta, A, Masana, L, Vinyoles Bargallo, E, Calvo Gomez, C, Gonzalez Juanatey JR, Cruz Fernandez JM, De La Cuesta Mayor, C, Duran Garcia, S, Jimenez Hernandez MD, Morales Portillo, C, Muniz Grijalvo, O, De Castro, R, Taverna Llaurado, E, Pons Amate JM, Terns Riera, M, Civeira Murillo, F, Linderfalk, C, Curiac, D, Saldeen-Nilehn, K, Koskinen, P, Khalili, P, Tortensson, I, Lindholm, Cj, Luts, A, Koskinen, Pt, Gottsater, A, Persson, Be, Mooe, T, Larnefeldt, H, Boman, K, Crisby, M, Rasmanis, G, Tengmark, Bo, Witt, N, Hagstrom, E, Viklund, J, Muller, C, Mach, F, Burnier, M, Nanchen, D, Wuerzner, G, Banyai, M, Moccetti, T, Miserez, Ar, Bilz, S, Weber, K, Lai, Wt, Chang, Kc, Ueng, Kc, Tsai, Wc, Chiang, Ce, Hou, C, Pei, D, Krittayaphong, R, Kiatchoosakun, S, Srimahachota, S, Boonyavarakul, A, Jintapakorn, W, Gullu, H, Onrat, E, Erkan, Af, Demirci, D, Sari, R, Ceyhan, C, Ari, H, Araz, M, Degertekin, M, Goktekin, O, Uresin, Ay, Yigit, Z, Akdeniz, B, Comlekci, A, Kayikcioglu, M, Sahin, T, Ozcan, T, Durakoglugil, E, Asamoah-Owusu, N, Reed, R, Bakhai, A, Dixon, L, Sharma, R, Avornyo, Aa, Jones, Af, Lip, G, Clark, R, Banerjee, M, Wakeling, J, Arden, C, Blagden, Md, Walukiewica, P, Marshall, A, Maxwell, Tg, Gunstone, Ae, Kadr, Hh, Patle, R, Arif, I, Jhund, Ps, Mckaig, G, Douglas, F, Mierzejewski, L, Turner, W, Sathyapalan, T, Ivan, P, Manoj, A, Rice, S, Collier, Dj, Nair, Dr, Thom, S, Fiore, G, De Belder, M, Price, D, Sobolewska, J, Martin, S, Takhar, A, Moriarty, A, Kondagunta, V, Myhill, T, Gibson, Jm, Cecil, Jt, Halcox, J, Annamalai, N, Gorog, Da, Mccormack, T, Pegge, N, Field, A, Adams, F, Klein, Jj, Busch, Rs, Bretton, Em, Jaffrani, N, Salacata, A, Assadourian, A, Gogia, Hs, Dyke, Ck, Rubenfire, M, Essandoh, Lk, Welker, Ja, Ledesma, G, Lupovitch, S, Delgado, Jp, Hendrix, El, Quyyumi, Aa, Riesenberg, Ra, Robertson, Dg, Weinstein, Dl, Weiss, R, Casaubon, L, Gammon, Rs, Brar, Hs, Bittar, Gd, Guarnieri, Tt, Ince CS Jr, Jrquraishi, Am, Saeed, S, Albert, M, Sotolongo, Rp, Bernard, Jv, Karlsbergg, Rp, Lepor, Ne, Kirby, We, Mclean, B, Miller, Ap, Ovalle, F, Townsend, Jc, Beckett, Pl, Eaves, Wb, West, Sh, Kosinski, Ej, Zarich, Sw, Mahal, Ss, Maw, K, Maynard, Km, Chen, Jc, Gelormini, J, Gottlieb, Dw, Gabra, Nw, Narayan, P, Sparks, J, Field, Jc, Willits, Vl, O’Steen, Mb, Pasquini, Ja, Sensebrenner, Jw, Yarows, Sa, Hiotis, L, Jagielo, Tj, Levinson, Dj, Diller, Pm, Kereiakes, Dj, Turner, Ta, Vincent, S, Camp, Ad, Denker, Ps, Manning, Mb, Rocco, Mb, Stamps, Hb, Strader, Jr, Uusinarkaus, Kt, Kennett, Jd, Leichter, Sb, Mcneil, Dl, Schumacher, Dr, Chang, Ar, Ellison, Hs, Updegrove, Jd, Hamroff, Gs, Kay, Js, Marar, Ie, Flores, E, Saini, S, Abdullah, S, Berk, Mr, Fordan, S, Joshi, Ph, Mccullough, Pa, Reynolds, Rd, Rosenstock, J, Sachson, Ra, Shammas, N, Fishbein, Gj, Randall, Wj, Henderson, Da, Nash, Ml, Barker, Ba, Cohen, Ss, Seidman, B, Odekirk, Ll, Grillo, Rs, Martinez, Lm, Multani, P, Alwine, Lk, Mcgarvey, Jf, Mollerus, Me, Miller, Ab, Kotek, Lw, Changlani, M, Zavaro, Sh, Munoz, F, Mehta, Pm, Helm, Rj, Farhat, Nz, Farsad, R, Raoof, Tj, Shultz, Jh, Geohas, Jg, Allaw, Ma, Dela Llana, A, Gutmann, Je, Inzerello, At, Alappat, P, George, Ar, Haddad, Tm, Lillestol, Mj, Grodman, R, Peniston, Jh, Wadud, K, Garcia, B, Hamilton, Me, Lerman, S, Perloff, De, Graff, A, Saxena, S, Alvarado, Op, Malik, A, Reddy, Rd, Kinzfogl, G, Cornett, Gm, Norwood, Pc, Gilbert, Jm, Willis, Jg, Mcgrew, F, Sharma, S, Castro, Ma, Cucher, Fh, Altafullah, Im, Khurana, S, Knutson, Tj, Kinnaman, Sj, Stuckey, T, Pudi, Kk, Mayfield, Rk, Funk, Gs, Nixon, Wa, Dor, I, Boyett, Be, Srivastava, S, Elosegui, Am, Isserman, Sm, Cheek, Hb, Promisloff, Sd, Tami, Lf, Zeig, S, fitz-Patrick, D, Dave, Kn, Ahmad, A, Arain, S, Ballantyne, Cm, Doshi, A, El Hafi SE, Feldman, J, Fragoso, Vg, Gilford, T, Hoffman, As, Pouzar, Je, Vivekananthan, K, Ansari, Sh, Strzinek, Ra, Crater, Ta, Robinson, Jg, Fulmer, Jj, Patel, Am, Pereira, Es, Stich, Ma, Sultan, S, Geskin, G, Ruoff, Ge, Gillespie, E, Bybee, Ka, Moriarty, Pm, Savin, V, Agaiby, Jm, Melucci, Mb, Jantzi, Cm, Davidson, E, Smith, Wb, Treasure, Cb, Wakefield, Ph, Deck, K, Edris, Ma, Gilmore, Rm, Seep, Mk, Andersen, Jl, Detweiler, Ro, Rosenfeld, Jc, Strobl, Dj, Steinhoff, Jp, Adams, A, Estevez, R, Molin, Cj, Kim, Cy, Dy, J, Fox, Ke, Farris, Nr, Wayne, Jd, Whitney, Rt, Randhawa, Pm, Mego, Dm, Macdolnald, L, Caputo, Rp, Rigolosi, R, Vannatta, B, Pacheco, Tr, El-Shahawy, M, Gonzalez, Ej, Guice, Mj, Cherlin, Rs, Bays, He, Shoukfeh, M, Morris, Fh, Loy, J, Vora, Sk, Staab, Pk, Frisoli, A, Kimmel, Ma, Cohen, Aj, Green, Cb, Whitlock, L, Butuk, Dj, Mccartney, Mj, Ables, Lr, Acosta, R, Alvarez, Jg, Barrera, Cm, Benitez, O, Berenguer, Ra, Breton, Cf, Chiong, R, Delgado, Mi, Dufreny, A, Fialkow, Ja, Franczek, S, Frias, Jj, Iglesias, C, Landron-Garcia, L, Llerena, Sn, Martinez, Rf, Miranda, Aa, Morytko, Ja, Rodriguez, Ij, Sotolongo, R, Suarez-Sarmiento, A, Terrelonge, Ae, Vaca, Ce, Venereo, Jm, Verdeza, C, Zeno, Ml, Chilka, S, Felten, Wr, Hartman, An, Shayani, Ss, Duprez, D, Knickelbine, T, Chambers, Jd, Cone, Cl, Broughton, R, Napoli, Mc, Seaton, Bl, Smith, Sk, Reedy, Ma, Kesani, Mk, Nicol, Pr, Stringam, So, Talano, Jv, Barnum, O, Desai, V, Montero, M, Jacks, Rk, Kostis, Jb, Owen, Jg, Makam, Sk, Grosman, I, Underberg, Ja, Masri, Be, Peters, Ss, Serje, J, Lenhard, Mj, Glover, R, Paraboschi, Cf, Lim, Eh, Connery, L, Kipgen, W, Bravo, P, Digiovanna, Mj, Tayoum, H, Gabriel, Jd, Ariani, Mk, Robinson, Mf, Clemens, Pc, Corder, Cn, Schifferdecker, B, Tahirkheli, Nk, Hurling, Rt, Rendell, Ms, Shivaswamy, V, Madu, Ij, Dahl, Cf, Ayesu, K, Kim, C, Barettella, Mb, Jamidar, Ha, Bloom, Sa, Vora, Kn, Ong, St, Aggarwala, G, Sack, G, Blaze, K, Krichmar, P, Murcia, A, Teltser, M, Villaman-Bencosme, Y, Fahdi, Ie, Williams, Dg, Lain, El, Garcia, Hl, Karim, Sn, Francyk, Dm, Gordon, Mb, Palchick, Ba, Mckenzie, Me, Gimness, Mp, Greiff, J, Ruiz-R, L, Vazquez-Tanus, Jb, Schlager, D, Connelly, T, Soroka, E, Hastings, Wl, O’Dea, Dj, Purdy, Da, Jackson, B, Arcanese, Ml, Strain, Je, Schmedtje JF Jr, Jrdavis, Mg, A, A, Prasada, S, Scott, Dl, Vukotic, G, Akhtar, N, Larsen, Dc, Rhudy, Jm, Zebrack, Js, Bailey, Sr, Grant, Dc, Mora, A, Perez, Ja, Reyes, Rg, Sutton, Jc, Brandon, Dm, First, Bp, Risser, Ja, Claudio, J, Figueroa-Cruz, Wl, Sosa-Padilla, Ma, Tan, Ae, Traboulssi, Ma, Morcos, Nc, Glaser, La, Bredlau, Ce, El Shahawy, M, Ramos, Mj, Kandath, Dd, Kaluski, E, Akright, L, Rictor, Kw, Pluto, Tm, Hermany, Pr, Bellingar, B, Clark, Gb, Herrod, Jn, Goisse, M, Hook, M, Barrington, P, Lentz, Jd, Singal, Dk, Gleason, Gp, Lipetz, Rs, Schuchard, Tn, Bonner, Jh, Forgosh, Lb, Lefebvre, Gc, Pierpoint, Be, Radin, Dm, Stoller, Sr, Segall, N, Shah, Sa, Ramstad, Ds, Nisnisan, Jm, Trippett, Jm, Benjamin, Sa, Labissiere, Jc, Nashed, An, Maaieh, M, Aslam, Aa, Mandviwala, M, Budoff, Mj, French, Wj, Vlach, Jj, Destefano, P, Bayron, Cj, Fraser, Nj, Sandberg, Jh, Fagan, Tc, Peart, Bc, Suryanarayana, Pg, Gupta, Dk, Lee, Mw, Bertolet, Bd, Hartley, Pa, Kelberman, M, Behmanesh, B, Buynak, Rj, Chochinov, Rh, Steinberg, Aa, Chandna, H, Bjasker, Kr, Perlman, Rl, Ball, Em, Pock, J, Singh, S, Baldari, D, Kaster, S, Lovell, Jp, Horowitz, Bs, Gorman, Ta, Pham, Dn, Landzberg, Js, Mootoo, Ki, Moon, E, Krawczyk, J, Alfieri, Ad, Janik, Mj, Herrington, Dm, Koilpillai, Rn, Waxler, Ar, Hoffman, Da, Sahul, Zh, Gumbiner, B, Cropp, A, Fujita, K, Garzone, P, Imai, K, Levisetti, M, Plowchalk, D, Sasson, S, Skaggs, J, Sweeney, K, Vincent, J., Curto, M, Ridker, P., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., Flather, M., Glynn, R., Gregoire, J., Jukema, J., Karpov, Y., Kastelein, J., Koenig, W., Lorenzatti, A., Manga, P., Masiukiewicz, U., Miller, M., Mosterd, A., Murin, J., Nicolau, J., Nissen, S., Ponikowski, P., Santos, R., Schwartz, P., Soran, H., White, H., Wright, R., Vrablik, M., Yunis, C., Shear, C., Tardif, J., SPIRE Cardiovascular Outcome Investigators, Averna, M., Brigham and Women's Hospital [Boston], Université Paris Diderot - Paris 7 (UPD7), Université Sorbonne Paris Cité (USPC), RS: CARIM - R3.02 - Hypertension and target organ damage, MUMC+: MA Alg Interne Geneeskunde (9), Interne Geneeskunde, Ridker, P. M., Glynn, R. J., Jukema, J. W., Kastelein, J. J. P., Nicolau, J. C., Santos, R. D., Schwartz, P. F., Wright, R. S., Shear, C. L., Tardif, J. -C., SPIRE Cardiovascular Outcome Investigator, Perrone, Filardi, P, Vascular Medicine, ACS - Amsterdam Cardiovascular Sciences, ACS - Pulmonary hypertension & thrombosis, and ACS - Atherosclerosis & ischemic syndromes
- Subjects
Male ,STATIN THERAPY ,Anticholesteremic Agents/adverse effects ,Antibodie ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Injections, Subcutaneous/adverse effects ,030204 cardiovascular system & hematology ,Bococizumab ,law.invention ,PCSK9 ,0302 clinical medicine ,Randomized controlled trial ,law ,Risk Factors ,GENETIC-VARIANTS ,Cardiovascular Disease ,Monoclonal ,Anticholesteremic Agent ,030212 general & internal medicine ,Myocardial infarction ,Treatment Failure ,Humanized ,Proprotein Convertase 9/antagonists & inhibitors ,Medicine(all) ,Antibodies ,Antibodies, Monoclonal, Humanized ,Anticholesteremic Agents ,Cardiovascular Diseases ,Cholesterol, LDL ,Double-Blind Method ,Female ,Follow-Up Studies ,Humans ,Hypercholesterolemia ,Injections, Subcutaneous ,Lipids ,Middle Aged ,Proprotein Convertase 9 ,Medicine (all) ,PCSK9 Inhibitors ,antibodies monoclonal humanized ,anticholesteremic agents ,cardiovascular diseases ,cholesterol, LDL ,double-blind method ,female ,follow-up studies ,humans ,hypercholesterolemia ,injections, subcutaneous ,lipids ,male ,middle aged ,proprotein convertase 9 ,risk factors ,treatment failure ,medicine (all) ,Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16] ,General Medicine ,Lipid ,3. Good health ,LDL/blood ,Multicenter Study ,Cholesterol ,TRIALS ,Cholesterol, LDL/blood ,Antibodies, Monoclonal, Humanized/adverse effects ,Randomized Controlled Trial ,subcutaneous ,lipids (amino acids, peptides, and proteins) ,Cardiovascular Diseases/prevention & control ,REDUCING LIPIDS ,Human ,medicine.medical_specialty ,animal structures ,Hypercholesterolemia/drug therapy ,Placebo ,Injections, Subcutaneou ,LDL ,Injections ,Follow-Up Studie ,EVENTS ,03 medical and health sciences ,Internal medicine ,medicine ,Journal Article ,Comparative Study ,METAANALYSIS ,Alirocumab ,business.industry ,Unstable angina ,Lipids/blood ,Risk Factor ,fungi ,Antibodies/blood ,ta3121 ,medicine.disease ,Surgery ,Evolocumab ,REDUCTION ,Humanized/adverse effects ,Subcutaneous/adverse effects ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death; 93% of the patients were receiving statin therapy at baseline. The trials were stopped early after the sponsor elected to discontinue the development of bococizumab owing in part to the development of high rates of antidrug antibodies, as seen in data from other studies in the program. The median follow-up was 10 months. RESULTS: At 14 weeks, patients in the combined trials had a mean change from baseline in LDL cholesterol levels of -56.0% in the bococizumab group and +2.9% in the placebo group, for a between-group difference of -59.0 percentage points (P/=70 mg per deciliter [1.8 mmol per liter] and the median follow-up was 7 months), major cardiovascular events occurred in 173 patients each in the bococizumab group and the placebo group (hazard ratio, 0.99; 95% confidence interval [CI], 0.80 to 1.22; P=0.94). In the higher-risk, longer-duration trial (in which the patients had a baseline LDL cholesterol level of >/=100 mg per deciliter [2.6 mmol per liter] and the median follow-up was 12 months), major cardiovascular events occurred in 179 and 224 patients, respectively (hazard ratio, 0.79; 95% CI, 0.65 to 0.97; P=0.02). The hazard ratio for the primary end point in the combined trials was 0.88 (95% CI, 0.76 to 1.02; P=0.08). Injection-site reactions were more common in the bococizumab group than in the placebo group (10.4% vs. 1.3%, P
- Published
- 2017
- Full Text
- View/download PDF
8. Ex vivo identification and characterization of a population of CD13(high) CD105(+) CD45(-) mesenchymal stem cells in human bone marrow
- Author
-
Muniz, C, Goncalves Grunho Teodosio, Cristina, Mayado, A, Amaral, AT, Matarraz, S, Barcena, P, Sanchez, ML, Alvarez-Twose, I, Diez-Campelo, M, Garcia-Montero, AC, Blanco, JF, del Canizo, MC, Montes, JDP, Orfao, A, Muniz, C, Goncalves Grunho Teodosio, Cristina, Mayado, A, Amaral, AT, Matarraz, S, Barcena, P, Sanchez, ML, Alvarez-Twose, I, Diez-Campelo, M, Garcia-Montero, AC, Blanco, JF, del Canizo, MC, Montes, JDP, and Orfao, A
- Abstract
Introduction: Mesenchymal stem cells (MSCs) are multipotent cells capable of self-renewal and multilineage differentiation. Their multipotential capacity and immunomodulatory properties have led to an increasing interest in their biological properties and therapeutic applications. Currently, the definition of MSCs relies on a combination of phenotypic, morphological and functional characteristics which are typically evaluated upon in vitro expansion, a process that may ultimately lead to modulation of the immunophenotypic, functional and/or genetic features of these cells. Therefore, at present there is great interest in providing markers and phenotypes for direct in vivo and ex vivo identification and isolation of MSCs. Methods: Multiparameter flow cytometry immunophenotypic studies were performed on 65 bone marrow (BM) samples for characterization of CD13(high) CD105(+) CD45(-) cells. Isolation and expansion of these cells was performed in a subset of samples in parallel to the expansion of MSCs from mononuclear cells following currently established procedures. The protein expression profile of these cells was further assessed on (paired) primary and in vitro expanded BM MSCs, and their adipogenic, chondrogenic and osteogenic differentiation potential was also determined. Results: Our results show that the CD13(high) CD105(+) CD45(-) immunophenotype defines a minor subset of cells that are systematically present ex vivo in normal/reactive BM (n = 65) and that display immunophenotypic features, plastic adherence ability, and osteogenic, adipogenic and chondrogenic differentiation capacities fully compatible with those of MSCs. In addition, we also show that in vitro expansion of these cells modulates their immunophenotypic characteristics, including changes in the expression of markers currently used for the definition of MSCs, such as CD105, CD146 and HLA-DR. Conclusions: BM MSCs can be identified ex vivo in normal/reactive BM, based on a robust CD13(high) CD105(+
- Published
- 2015
9. A Molecular Strategy For A Faster Detection Of Resistant Tuberculosis
- Author
-
alcazar ramirez, jose, primary, Martinez-Lirola, Miguel, additional, Alonso, M, additional, Montiel, N, additional, Navarro, Y, additional, Cabeza, I, additional, Sanchez-Yebra, W, additional, Sanchez, ML, additional, García-Viedma, D, additional, and Linde, F, additional
- Published
- 2010
- Full Text
- View/download PDF
10. Validation of a Spanish language dyspepsia questionnaire
- Author
-
Goldman, JW, primary, Halperin, D, additional, Sanchez, ML, additional, Ley, C, additional, and Parsonnet, J, additional
- Published
- 1998
- Full Text
- View/download PDF
11. Apolipoprotein E epsilon4, Alzheimer's disease, and cognitive performance in elderly Mexican Mestizos.
- Author
-
Villalpando-Berumen JM, Mejia-Arango S, Aguilar-Salinas CA, Ordonez-Sanchez ML, and Gutierrez-Robledo LM
- Abstract
OBJECTIVES: To determine the relationship between apolipoprotein E (APOE) epsilon4 and Alzheimer's disease (AD) in the Mexican Mestizo population, as well as its effects on the cognitive profile of AD and elderly Mestizos without dementia. DESIGN: Cross-sectional analysis of a cohort study. SETTING: Evaluations were conducted at the geriatrics clinic of an academic medical hospital in Mexico City. PARTICIPANTS: Forty-nine elderly subjects with AD and 141 controls selected from a representative sample of Mexican Mestizos aged 65 to 96 who participated in the Prevalence Survey of Dementia in the Mexico City Elderly Population cohort. MEASUREMENTS: All subjects underwent APOE genotypification and a comprehensive clinical and neuropsychological evaluation. RESULTS: There were no significant differences in epsilon3 and epsilon4 frequencies between the subjects with and without AD and a tendency toward higher epsilon4 and lower epsilon3 allele frequencies in subjects aged 75 and older. No association was found between APOE epsilon4 and the presence of AD. The age-, sex-, and education-adjusted risk for AD associated with at least one epsilon4 allele was 1.01 (95% confidence interval=0.45-2.23). Performance on a long-term visual memory test was significantly worse in APOE epsilon4 carriers than in APOE epsilon3 carriers only in the group with AD. CONCLUSION: APOE epsilon4 did not increase the risk for AD in this Mexican Mestizo elderly urban population sample, although the presence of this allele seems to modify its clinical expression. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
12. Using the Short Form 6D, as an overall measure of health, to predict damage accrual and mortality in patients with systemic lupus erythematosus: XLVII, results from a multiethnic US cohort.
- Author
-
Fernández M, Alarcón GS, McGwin G Jr, Sanchez ML, Apte M, Vilá LM, Reveille JD, and LUMINA Study Group
- Published
- 2007
13. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women.
- Author
-
Fernández M, Calvo-Alén J, Alarcón GS, Roseman JM, Bastian HM, Fessler BJ, McGwin G Jr., Vilá LM, Sanchez ML, Reveille JD, and LUMINA Study Group
- Abstract
OBJECTIVE: To determine the differences in clinical manifestations, disease activity, damage accrual, and medication use in systemic lupus erythematosus (SLE) patients as a function of menopausal status at disease onset. METHODS: Women with SLE as per the criteria of the American College of Rheumatology, with disease duration of =5 years and of Hispanic (Texas and Puerto Rico ancestries), African American, and Caucasian ethnicity, from LUMINA (LUpus in MInorities, NAture versus nurture), a multiethnic, longitudinal cohort, were studied. Menopause at the time of disease onset was defined as self-report of climacteric symptoms, and/or amenorrhea lasting >6 months, and/or oophorectomy, and/or increased follicle-stimulating hormone values for reproductive-age women, and/or treatment with hormone replacement therapy. Patients were divided into premenopausal and postmenopausal categories. Socioeconomic status, cumulative clinical manifestations, disease activity (at study entry or time 0, last visit, and over time), as measured by the Systemic Lupus Activity Measure, and damage accrual, as measured by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (at time 0 and at last visit) were compared between the 2 groups of women. Multivariable models were then examined making adjustments for all possible known confounders. Dependent variables in the models were renal involvement, damage accrual, arterial vascular events, and venous thrombosis. RESULTS: Five hundred eighteen women from the LUMINA cohort were included; 436 (84.2%) were premenopausal and 82 (15.8%) were postmenopausal. Disease onset after menopause was more common among Caucasians. Renal involvement was more common in premenopausal women, whereas vascular arterial events were more frequent in postmenopausal women. All other disease manifestations, as well as disease activity, were comparable between both groups. The presence of damage accrual at time 0 and study end was more frequent in postmenopausal women. Age, rather than menopausal status, independently contributed to damage accrual, renal involvement, and vascular arterial events in these women. CONCLUSION: A hypoestrogenemic state secondary to menopause appears not to be protective against disease activity and damage accrual. Age rather than menopausal status is a strong independent predictor of damage accrual and of vascular events in women with lupus. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
14. Systemic lupus erythematosus in three ethnic groups. XVIII. Factors predictive of poor compliance with study visits.
- Author
-
Uribe AG, Alarcón GS, Sanchez ML, McGwin G Jr., Sandoval R, Fessler BJ, Bastian HM, Friedman AW, Baethge BA, Reveille JD, and LUMINA (Lupus in Minorities, Nature versus Nurture) Study Group
- Published
- 2004
15. Systemic lupus erythematosus in three ethnic groups. XIV. Poverty, wealth, and their influence on disease activity.
- Author
-
Alarcón GS, McGwin G Jr., Sanchez ML, Bastian HM, Fessler BJ, Friedman AW, Baethge BA, Roseman J, Reveille JD, and LUMINA (Lupus in Minorities, nature versus nurture) Study Group
- Published
- 2004
16. Systemic lupus erythematosus in three ethnic groups. XI. Sources of discrepancy in perception of disease activity: a comparison of physician and patient visual analog scale scores.
- Author
-
Alarcón GS, McGwin G Jr., Brooks K, Roseman JM, Fessler BJ, Sanchez ML, Bastian HM, Friedman AW, Baethge BA, Reveille JD, and LUMINA (Lupus in Minority populations: Nature versus nurture) Study Group
- Published
- 2002
17. Systemic lupus erythematosus in three ethnic groups. X. Measuring cognitive impairment with the Cognitive Symptoms Inventory.
- Author
-
Alarcón GS, Cianfrini L, Bradley LA, Sanchez ML, Brooks K, Friedman AW, Baethge BA, Fessler BJ, Bastian HM, Roseman JM, McGwin G Jr., Reveille JD, and Lumina (Lupus in Minority populations: Nature versus nurture) Study Group
- Published
- 2002
18. Ensemble-averaged variational transition state theory with optimized multidimensional tunneling
- Author
-
Truhlar, Dg, Gao, Jl, Alhambra, C., Corchado, J., Mireia Garcia Viloca, Sanchez, Ml, Kesavan, Ld, Poulsen, T., and Villa, J.
19. The interface of electronic structure theory and dynamics for the calculation of chemical reaction reaction rate constants
- Author
-
Truhlar, Dg, Chuang, Yy, Corchado, Jc, Fast, P., Radhakrishnan, Ml, Rodgers, Jm, Sanchez, Ml, Villa, J., Lynch, B., and Cramer, Cj
20. Chemical kinetics of systems with complex reaction paths: Ensemble-averaged variational transition state theory with multidimensional tunneling
- Author
-
Truhlar, Dg, Gao, Jl, Garcia-Viloca, M., Poulsen, T., Alhambra, C., Juan Manuel Corchado, and Sanchez, Ml
21. Ensemble-averaged variational transition state theory with multidimensional tunneling
- Author
-
Truhlar, Dg, Gao, Jl, Garcia-Viloca, M., Poulsen, T., Pu, Jz, Alhambra, C., Juan Manuel Corchado, and Sanchez, Ml
22. CagA antibodies and serum gastrin as screening tests for gastric preneoplastic conditions
- Author
-
Witherell, H., Sanchez, ML, Guarner, J., Halperin, D., Ley, C., Mohar, A., and Parsonnet, J.
- Published
- 1998
- Full Text
- View/download PDF
23. Basophil Activation Test Positivity Decreases With Time in Immediate Allergic Reactions to Proton Pump Inhibitors.
- Author
-
Fernandez-Santamaria R, Salas M, Ariza A, Jiménez MA, González-Mendiola MR, Sanchez ML, Boteanu C, Mayorga C, Fernandez TD, Torres MJ, and Laguna JJ
- Published
- 2024
- Full Text
- View/download PDF
24. Changes in Diet During Orthodontic Treatment in Adolescents. A Literature Review
- Author
-
Tombal É, Nicolas E, Munoz Sanchez ML, Linas N, and El Helou M
- Subjects
- Adolescent, Humans, Feeding Behavior physiology, Diet methods, Orthodontics, Corrective methods, Orthodontics, Corrective adverse effects
- Abstract
Introduction: Fixed orthodontic treatment, typically initiated during adolescence (a crucial period of growth) raises interest in evaluating dietary modifications resulting from their implementation, providing essential information for formulating appropriate dietary advice. This systematic literature review aims to assess dietary changes in adolescents following orthodontic treatment., Material and Methods: An electronic search was conducted in the PubMed database with no time restrictions, following PRISMA guidelines. A combination of MeSH and non-MeSH terms, with no deadline, was applied, followed by a rigorous assessment of selected articles. The latest search was conducted on September the 20 th, 2023., Results: Among the initially identified 224 articles, only nine studies met the inclusion criteria. All, except one study, reported significant dietary modifications after treatment initiation., Conclusion: The installation of fixed orthodontic treatment in adolescents alters dietary habits, favoring soft foods. Anticipating the consequences on growth and diet habits is crucial, recommending tailored dietary advice before appliance placement. The registration number for this review on PROSPERO is CRD42023454959.
- Published
- 2024
- Full Text
- View/download PDF
25. Homology-based identification and structural analysis of Pangasius hypophthalmus Annexins and Serine proteases to search molecules for wound healing applications.
- Author
-
Avila Rodríguez MI, Velez Rueda AJ, Hernández-Pérez J, Benavides J, and Sanchez ML
- Abstract
Chronic wounds and burns are a worldwide healthcare problem that erodes patients' well-being and healthcare systems. This silent and costly epidemic requires new, cost-efficient solutions to improve patients' physical and economic welfare. Eschar-degrading vegetal and bacterial proteases have been utilized as a solution. However, these proteins are evolutionarily far from those present in human wound healing. Serine protease (SP) and annexin (ANX) proteins interact within the skin healing process. A homology-based identification pipeline can help in discovering selective human SP and ANX analogs in the epithelial tissue of the fast-healing species, Pangasius hypophthalmus . In the present work, we found 14 candidates for RT-PCR in P. hypophthalmus using homology inference. The genetically detected candidates were then structurally and sequentially analyzed to understand their possible relation to SPs and ANXs involved in human wound healing. A total of six TBLASTN/BLASTX candidates (four SPs and two ANXs) were detected in P. hypophthalmus skin. Structural analysis revealed that all SP candidates resembled human KLK4, KLK5, KLK6, and KLK8, whereas all ANX only resembled human ANXA4. Structure and sequence analysis revealed high conservation of ANX Ca
2+ binding sites (GDXD) and SP catalytic triad (HDS) motifs. In addition, structural analysis revealed that SP substrate selectivity position 186 was the main difference between human KLK5 and P. hypophthalmus SPs. These findings may allow the proposal and testing of more selective formulations, broadening treatments beyond debridement., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 The Authors.)- Published
- 2024
- Full Text
- View/download PDF
26. X-ray photoelectron and NEXAFS spectroscopy of thionated uracils in the gas phase.
- Author
-
Mayer D, Handrich M, Picconi D, Lever F, Mehner L, Murillo-Sanchez ML, Walz C, Titov E, Bozek J, Saalfrank P, and Gühr M
- Abstract
We present a comprehensive, combined experimental and theoretical study of the core-level photoelectron and near-edge x-ray absorption fine structure (NEXAFS) spectra of 2-thiouracil, 4-thiouracil, and 2,4-dithiouracil at the oxygen 1s, nitrogen 1s, carbon 1s, and the sulfur 2s and 2p edges. X-ray photoelectron spectra were calculated using equation-of-motion coupled-cluster theory (EOM-CCSD), and NEXAFS spectra were calculated using algebraic diagrammatic construction and EOM-CCSD. For the main peaks at O and N 1s as well as the S 2s edge, we find a single photoline. The S 2p spectra show a spin-orbit splitting of 1.2 eV with an asymmetric vibrational line shape. We also resolve the correlation satellites of these photolines. For the carbon 1s photoelectrons, we observe a splitting on the eV scale, which we can unanimously attribute to specific sites. In the NEXAFS spectra, we see very isolated pre-edge features at the oxygen 1s edge; the nitrogen edge, however, is very complex, in contrast to the XPS findings. The C 1s edge NEXAFS spectrum shows site-specific splitting. The sulfur 2s and 2p spectra are dominated by two strong pre-edge transitions. The S 2p spectra show again the spin-orbit splitting of 1.2 eV., (© 2024 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).)
- Published
- 2024
- Full Text
- View/download PDF
27. [Adrenal insufficiency and corticosteroid weaning: The synacthen test is out, morning serum cortisol is in].
- Author
-
Rivière É, Nunes-Sanchez ML, and Haissaguerre M
- Published
- 2024
- Full Text
- View/download PDF
28. 'I want to be a different kind of father': a qualitative analysis of adolescent fatherhood in Perú.
- Author
-
Jimenez Sanchez ML, Gamarra P, Brunner J, Williams HA, LaNoire M, Barrios YV, Cruz VO, Rondon MB, Gelaye B, and Levey EJ
- Abstract
Adolescent parents and their offspring experience worse health outcomes throughout the life course. While over 90% of adolescent births occur in low- and middle-income countries, data from many such countries are lacking, particularly from fathers. This qualitative study conducted in Lima, Peru characterises the experience of adolescent fathers and identifies potential intervention targets. Interviews with young fathers and the mothers of their children were coded and analysed using thematic analysis and a grounded theory approach. Factors impacting their experience included family support, changes in their relationship with their partner, gender dynamics, and financial pressure. The study identified family and couple conflict, gendered expectations, and the father's personal development as potential intervention targets. Further research is needed to develop interventions that effectively engage adolescent fathers in low- and middle-income countries such as Peru, and support their transition to fatherhood.
- Published
- 2024
- Full Text
- View/download PDF
29. Age related impairments in ingestion from a large population based-sample.
- Author
-
Hennequin M, El Osta N, Munoz-Sanchez ML, Vandenberghe Descamps M, Andreeva VA, Feron G, Nicolas E, Pereira B, Peyron MA, Cousson PY, Sulmont-Rosse C, and Faulks D
- Subjects
- Humans, Adolescent, Adult, Aged, Aged, 80 and over, Oral Health, Mastication, Food, Quality of Life, Xerostomia epidemiology
- Abstract
Objectives: Epidemiological data regarding the evolution of problems related to mastication and swallowing with age are lacking. This study aims to (i) describe changes in oral function with age, using data from a large French population, (ii) validate online, self-report uses of an ICF questionnaire in older persons, and (iii) assess whether impairment is related to avoidance of certain foods, xerostomia, body mass index (BMI) and oral health related quality of life (OHRQoL)., Methods: Volunteers aged ≥18 years with internet access completed a series of questionnaires on sociodemographic, anthropometric and oral health characteristics (oral function, Xerostomia Index (XI), OHRQoL, reasons for avoidance of certain food). Oral function was assessed using items derived from the International Classification of Functioning (ICF). Five ICF items related to ingestion function and six items related to activities and participation were used. A validation study was undertaken to identify those with poor chewing ability and low salivary flow amongst older participants reporting impairment., Findings: 39 597 individuals were included. The prevalence of individuals with impairment for ICF items related to ingestion function and oral activity (eating, drinking and speaking), and the percentage of participants with poor OHRQoL increased significantly with age (p < 0.001). Each ICF item was significantly associated with OHRQoL (p < 0.001), XI (p < 0.001), BMI (p < 0.001) and avoidance of certain food due to chewing or swallowing difficulties., Conclusion: Overall, 21.5% and 13.5% of the study population had chewing and/or biting impairments respectively, which might affect food selection and consumption. These findings raise individual and population-based issues. Further studies are needed to assess whether impairment in oral function might increase frailty in older individuals, and also to compare data with those from other countries., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
30. Liquid crystal wave plate operating close to 18 THz.
- Author
-
Novelli F, Friebel P, Murillo-Sanchez ML, Michael Klopf J, and Cattaneo L
- Abstract
Controlling the properties of mid- and far-infrared radiation can provide a means to transiently alter the properties of materials for novel applications. However, a limited number of optical elements are available to control its polarization state. Here we show that a 15-µm thick liquid crystal cell containing 8CB (4-octyl-4'-cyanobiphenyl) in the ordered, smectic A phase can be used as a phase retarder or wave plate. This was tested using the bright, short-pulsed (∼1 ps) radiation centered at 16.5 µm (18.15 THz) that is emitted by a free electron laser at high repetition rate (13 MHz). These results demonstrate a possible tool for the exploration of the mid- and far-infrared range and could be used to develop novel metamaterials or extend multidimensional spectroscopy to this portion of the electromagnetic spectrum.
- Published
- 2024
- Full Text
- View/download PDF
31. Exposure to parental depression in adolescence and proinflammatory phenotypes 20 years later.
- Author
-
Ehrlich KB, Celia-Sanchez ML, Yu T, Heard-Garris N, Chen E, Miller GE, and Brody GH
- Subjects
- Adult, Humans, Adolescent, Inflammation, Parents, Phenotype, Depression, Hydrocortisone
- Abstract
Although the biological embedding model of adversity proposes that stressful experiences in childhood create a durable proinflammatory phenotype in immune cells, research to date has relied on study designs that limit our ability to make conclusions about whether the phenotype is long-lasting. The present study leverages an ongoing 20-year investigation of African American youth to test research questions about the extent to which stressors measured in childhood forecast a proinflammatory phenotype in adulthood, as indicated by exaggerated cytokine responses to bacterial stimuli, monocyte insensitivity to inhibitory signals from hydrocortisone, and low-grade inflammation. Parents reported on their depressive symptoms and unsupportive parenting tendencies across youths' adolescence. At age 31, youth participants (now adults) completed a fasting blood draw. Samples were incubated with lipopolysaccharide and doses of hydrocortisone to evaluate proinflammatory processes. Additionally, blood samples were tested for indicators of low-grade inflammation, including IL-6, IL-8, IL-10, and TNF-α, and soluble urokinase plasminogen activator receptor. Analyses revealed that parental depression across youths' adolescence prospectively predicted indicators of proinflammatory phenotypes at age 31. Follow-up analyses suggested that unsupportive parenting mediated these associations. These findings suggest that exposure to parental depression in adolescence leaves an imprint on inflammatory activity that can be observed 20 years later., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
32. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
- Author
-
Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, Leighl N, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, and Seymour L
- Subjects
- Humans, Male, Aged, Female, Pemetrexed adverse effects, Platinum therapeutic use, Canada epidemiology, Antineoplastic Combined Chemotherapy Protocols, Mesothelioma, Malignant drug therapy, Mesothelioma drug therapy, Mesothelioma chemically induced
- Abstract
Background: Pleural mesothelioma usually presents at an advanced, incurable stage. Chemotherapy with platinum-pemetrexed is a standard treatment. We hypothesised that the addition of pembrolizumab to platinum-pemetrexed would improve overall survival in patients with pleural mesothelioma., Methods: We did this open-label, international, randomised phase 3 trial at 51 hospitals in Canada, Italy, and France. Eligible participants were aged 18 years or older, with previously untreated advanced pleural mesothelioma, with an Eastern Cooperative Oncology Group performance status score of 0 or 1. Patients were randomly assigned (1:1) to intravenous chemotherapy (cisplatin [75 mg/m
2 ] or carboplatin [area under the concentration-time curve 5-6 mg/mL per min] with pemetrexed 500 mg/m2 , every 3 weeks for up to 6 cycles), with or without intravenous pembrolizumab 200 mg every 3 weeks (up to 2 years). The primary endpoint was overall survival in all randomly assigned patients; safety was assessed in all randomly assigned patients who received at least one dose of study therapy. This trial is registered with ClinicalTrials.gov, NCT02784171, and is closed to accrual., Findings: Between Jan 31, 2017, and Sept 4, 2020, 440 patients were enrolled and randomly assigned to chemotherapy alone (n=218) or chemotherapy with pembrolizumab (n=222). 333 (76 %) of patients were male, 347 (79%) were White, and median age was 71 years (IQR 66-75). At final analysis (database lock Dec 15, 2022), with a median follow-up of 16·2 months (IQR 8·3-27·8), overall survival was significantly longer with pembrolizumab (median overall survival 17·3 months [95% CI 14·4-21·3] with pembrolizumab vs 16·1 months [13·1-18·2] with chemotherapy alone, hazard ratio for death 0·79; 95% CI 0·64-0·98, two-sided p=0·0324). 3-year overall survival rate was 25% (95% CI 20-33%) with pembrolizumab and 17% (13-24%) with chemotherapy alone. Adverse events related to study treatment of grade 3 or 4 occurred in 60 (27%) of 222 patients in the pembrolizumab group and 32 (15%) of 211 patients in the chemotherapy alone group. Hospital admissions for serious adverse events related to one or more study drugs were reported in 40 (18%) of 222 patients in the pembrolizumab group and 12 (6%) of 211 patients in the chemotherapy alone group. Grade 5 adverse events related to one or more drugs occurred in two patients on the pembrolizumab group and one patient in the chemotherapy alone group., Interpretation: In patients with advanced pleural mesothelioma, the addition of pembrolizumab to standard platinum-pemetrexed chemotherapy was tolerable and resulted in a significant improvement in overall survival. This regimen is a new treatment option for previously untreated advanced pleural mesothelioma., Funding: The Canadian Cancer Society and Merck & Co., Competing Interests: Declaration of interests MP has received grants for research to institution from AstraZeneca and Roche; payment for educational events from Astellas, Pfizer, and AstraZeneca; and received drugs for research from Roche and AstraZeneca. GLR received consulting fees from MSD, BMS, AstraZeneca, Roche, Novartis, Lilly, Amgen, Sanofi, Pfizer, Takeda, GSK, and Italfarmaco; received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from MSD, BMS, AstraZeneca, Roche, Novartis, Lilly, Amgen, Sanofi, Pfizer, Takeda, GSK, and Italfarmaco; received support for attending meetings or travel from Roche, MSD, BMS, and Amgen; has participated on a Data Safety Monitoring Board or Advisory Board for MSD, BMS, AstraZeneca, Roche, Novartis, Lilly, Amgen, Sanofi, Pfizer, Takeda, GSK, and Italfarmaco; and has other financial or non-financial interests from MSD, BMS, AstraZeneca, Roche, Novartis, Amgen, Sanofi, Pfizer, Takeda, and GSK. YL holds stock or stock options from Merck. SL received consulting fees from Lilly, MSD, Sanofi, and AbbVie and payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from AstraZeneca. AS received grants or contracts (payments to institution) from MSD, BMS, AstraZeneca, Roche, and Amphera; received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from AstraZeneca, BMS, MSD, and Roche; received support for attending meetings or travel from AstraZeneca, BMS, MSD, and Roche; and participated on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, BMS, MSD, and Roche. MF received consulting fees from AstraZeneca, BMS, and Takeda and received honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from AstraZeneca, BMS, and Takeda. SAL has participated on a Data Safety Monitoring Board or Advisory Board for Sanofi and Bayer. JRG received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from AstraZeneca and BMS. PB received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Merck and participated on a Data Safety Monitoring Board or Advisory Board for Mirati and AbbVie. NL has received editorial support from EMD Serono; received grants to institute (unrelated) from Amgen, AstraZeneca, Bayer, BMS, Eli Lilly, EMD Serono, Guardant Health, Inivata, Janssen, Merck/MSD, Novartis, Pfizer, Roche, and Takeda; received honoraria or travel funding for CME lectures (unrelated) from AstraZeneca, Beigene, BMS, Janssen, Merck, Novartis, and Takeda; and participated on a Data Safety Monitoring Board or Advisory Board for Mirati, Helsinn, and Daichii Sankyo. LS has received grants or contracts to institution to support clinical trial from AstraZeneca, Merck, Bayer, Novartis, Repare, GSK, and Janssen and holds stock or stock options from AstraZeneca. DED has received research grants from CIHR, CancerCare Manitoba Foundation, and AstraZeneca; received research grants and salary awards from Manitoba Medical Services Foundation; received payment for educational events from Roche, Boehringer Ingelheim, and BMS; served on an advisory board for Merck, AstraZeneca, Pfizer, Jazz Pharmaceuticals, and Novartis; has acted in a leadership or fiduciary role in a board, society, committee or advocacy group, paid or unpaid for Lung Cancer Canada (Medical Advisory Committee), Canadian Association of Medical Oncologists (Chair, Fellowship Committee), and Canadian Cancer Trials Group (Chair, Small Cell Lung Cancer Working Group); and received equipment, materials, drugs, medical writing, gifts, or other services from AstraZeneca (Medical writing assistance on a small-cell lung cancer paper). QC has received grants to institution from Alkermes, Amgen, Apollomics, Astellas, AstraZeneca, Bicycle, BMS, Conjupro, Decipher, Eli Lilly, Esperas, Exactis, GSK, iTEOS, Kelun, Merck, Mirati, Nuvalent, Ocellaris, Pfizer, Rvolution Medicines, Roche, SeaGen, Spectrum, and Treadwell; received consulting fees from Amgen, AnHeart, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK, Jazz Pharmaceuticals, Janssen, Merck and Co, Novartis, Pfizer, Roche, and Takeda; received payment for speaking or presentations from AstraZeneca; acted on an advisory board for Amgen, AnHeart, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK, Jazz Pharmaceuticals, Janssen, Merck and Co, Novartis, Pfizer, Roche, and Takeda; acted on a Data Safety Monitoring Committee for Merck and KGaA; and occupied a leadership or fiduciary role in a board, society, committee, or advocacy group, paid or unpaid for Lung Cancer Canada and Canadian Mesothelioma Foundation. CWL has served as a member of the Board of Directors for Canadian Mesothelioma Foundation. LG received grants or contracts to institution from BMS, MSD, Takeda, Pfizer, Roche, Amgen, Sanofi, Janssen, Lilly, and Novartis; received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from BMS, MSD, Takeda, Pfizer, Roche, Amgen, Sanofi, Janssen, Lilly, and Novartis; received support for attending meetings or travel from Pfizer, MSD, AstraZeneca, and Takeda; and participated on a Data Safety Monitoring Board or Advisory Board for Inhatarget Therapeutics. XQ received support for attending meetings or travel from Pfizer (ESMO 2022), Janssen (ASCO 2022), and Sanofi (ASCO 2023). VW received consulting fees from Amgen; received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Amgen, AstraZeneca, Bristol Myers Squibb, MSD, Roche, and Sanofi; received support for attending meetings or travel from AstraZeneca, Bristol Myers Squibb, Janssen, MSD, Roche, and Sanofi; and participated on a Data Safety Monitoring Board or Advisory Board for Amgen, AstraZeneca, and Ipsen. GZ received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Inventiva Pharma, Lilly, MSD Oncology, Pfizer, and Roche; acted in a consulting or advisory role for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Da Volterra, Inventiva Pharma, MSD Oncology, Pfizer, and Roche; received research funding from AstraZeneca, Bristol-Myers Squibb, Pfizer, Roche, and Takeda; and received travel, accommodations, and expenses from AbbVie, AstraZeneca, Bristol-Myers Squibb, Lilly, Pfizer, and Roche. MLS received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from BMS and support for attending meetings or travel from Pfizer (ESMO 2022). AM received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Roche, AstraZeneca, BMS, MSD, Pfizer, Takeda, Boehringer, Sanofi, Lilly, Novartis, and Italfarmaco and participated on a Data Safety Monitoring Board or Advisory Board for Roche, AstraZeneca, Pfizer, MSD, and Takeda. FG received consulting fees from Novocure, BMS, Novartis, PharmaMar, Pierre Fabre, and MSD; received payment for speaker bureau from Novocure; received support for attending meetings or travel from Novartis, MSD, BMS, PharmaMar, and Pierre Fabre. SD received payment for presentations from Novartis, Pierre-Fabre, and BMS and travel and accommodation support during meetings from Istituto Gentili, Novartis, Pierre-Fabre, and BMS. GLC received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Novocure and BMS and participated on a Data Safety Monitoring Board or Advisory Board for Novocure. PAZ received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Merck Sharp and Dohme, Astellas, Janssen, Sanofi, Ipsen, Pfizer, Novartis, Bristol Meyer Squibb, Amgen, AstraZeneca, Roche, and Bayer; received support for attending meetings or travel from Merck Sharp and Dohme, Astellas, Janssen, Sanofi, Ipsen, Pfizer, Novartis, Bristol Meyer Squibb, Amgen, AstraZeneca, Roche, and Bayer; and participated on a Data Safety Monitoring Board or Advisory Board for Merck Sharp and Dohme, Astellas, Janssen, Sanofi, Ipsen, Pfizer, Novartis, Bristol Meyer Squibb, Amgen, AstraZeneca, Roche, and Bayer. MM received support for attending meetings or travel from Roche, Pfizer, and Novartis. FLC received consulting fees from Takeda, Amgen, Novartis, AstraZeneca, and Roche; received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Takeda, Amgen, Novartis, AstraZeneca, and Roche; and received support for attending meetings or travel from Takeda and Amgen. CG received consulting fees from Karyopharm, Menarini, and Roche; received payment or honoraria for lectures, presentations, speakers' bureaux, manuscript writing, or educational events from MSD, BMS, Novartis, Amgen, Sanofi, Eli Lilly, GSK, Roche, Takeda, Boehringer, AstraZeneca, and Pfizer; and participated on a Data Safety Monitoring Board or Advisory Board for MSD, BMS, Novartis, Amgen, Sanofi, Eli Lilly, GSK, Roche, Takeda, Boehringer Ingelheim, AstraZeneca, and Pfizer. FP received partial funding to institution and experimental study drug from Pfizer; received financial support to institution from Roche, Bayer, AstraZeneca, Pfizer, Incyte, Tesaro/GSK, and Merck; and received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Bayer, Pierre Fabre, AstraZeneca, Incyte, Ipsen, Clovis, Astellas, Sanofi, Roche, and Pfizer. All other authors declare no competing interests., (Copyright © 2023 Elsevier Ltd. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
33. Physical Demands in the Worst-Case Scenarios of Elite Futsal Referees Using a Local Positioning System.
- Author
-
Martinez-Torremocha G, Sanchez-Sanchez J, Alonso-Callejo A, Martin-Sanchez ML, Serrano C, Gallardo L, Garcia-Unanue J, and Felipe JL
- Subjects
- Lipopolysaccharides, Heart Rate, Running, Football, Athletic Performance
- Abstract
The aim of this study is to analyze the worst-case scenarios of professional futsal referees during the first and second half of official matches in the Spanish Futsal Cup using a Local Positioning System (LPS) for monitoring their movement patterns. Eight professional futsal referees (40 ± 3.43 years; 1.80 ± 0.03 m; 72.84 ± 4.01 kg) participated in the study. The external load (total distance, high-speed running distance and efforts, sprint distance and efforts, and accelerations and decelerations distances) of the referees was monitored and collected using an LPS. The results revealed significant differences in the worst-case scenarios of the futsal referees during the match according to the time window analyzed ( p < 0.05). The longest time windows (120 s, 180 s, and 300 s) showed lower relative total distances in the worst-case scenarios ( p < 0.05). The high-speed running distances were significatively higher in the first half for the 120 s (+2.65 m·min
-1 ; ES: 1.25), 180 s (+1.55 m·min-1 ; ES: 1.28), and 300 s (+0.95 m·min-1 ; ES: 1.14) time windows ( p < 0.05). No differences were found between the first and second half for the high-intensity deceleration distance ( p > 0.05). These results will serve to prepare the referees in the best conditions for the competition and adapt the training plans to the worst-case scenarios.- Published
- 2023
- Full Text
- View/download PDF
34. Monitoring and tracking the spread of SARS-CoV-2 in Asturias, Spain.
- Author
-
Gonzalez-Alba JM, Rojo-Alba S, Perez-Martinez Z, Boga JA, Alvarez-Arguelles ME, Gomez J, Herrero P, Costales I, Alba LM, Martin-Rodriguez G, Campo R, Castelló-Abietar C, Sandoval M, Abreu-Salinas F, Coto E, Rodriguez M, Rubianes P, Sanchez ML, Vazquez F, Antuña L, Álvarez V, and Melón García S
- Abstract
Mutational analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can quantify the relative importance of variants over time, enable dominant mutations to be identified, and facilitate near real-time detection, comparison and tracking of evolving variants. SARS-CoV-2 in Asturias, an autonomous community of Spain with a large ageing population, and high levels of migration and tourism, was monitored and tracked from the beginning of the pandemic in February 2020 until its decline and stabilization in August 2021, and samples were characterized using whole genomic sequencing and single nucleotide polymorphisms. Data held in the GISAID database were analysed to establish patterns in the appearance and persistence of SARS-CoV-2 strains. Only 138 non-synonymous mutations occurring in more than 1 % of the population with SARS-CoV-2 were found, identifying ten major variants worldwide (seven arose before January 2021), 19 regional and one local. In Asturias only 17 different variants were found. After vaccination, no further regional major variants were found. Only half of the defined variants circulated and no new variants were generated, indicating that infection control measures such as rapid diagnosis, isolation and vaccination were efficient., Competing Interests: The authors declare no conflict of interest., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
35. In Vitro Resistance of Natural Molars vs. Additive-Manufactured Simulators Treated with Pulpotomy and Endocrown.
- Author
-
Munoz-Sanchez ML, Gravier A, Francois O, Nicolas E, Hennequin M, and Decerle N
- Abstract
Endocrowns are designed to restore endodontically treated teeth with root canal treatment (Rct). Recently, endocrowns were proposed for teeth treated with full pulpotomy (FP). No data exist on in vitro evaluations for this combination. This study aimed to evaluate the mechanical behavior of pulpotomy-treated teeth with endocrowns according to different protocols for preparation design and materials and to assess whether 3D-printed resin simulators could be a reliable alternative for human teeth during in vitro strength tests. One hundred and ten extracted natural molars were randomized into 11 groups according to the type of endodontic treatment, the material used, and the design of peripheric preparation. One hundred and ten resin simulators were separated similarly. The samples were embedded in epoxy resin blocks before being subjected to oblique compressive load until failure. For natural teeth, the variance analysis separated two homogeneous groups, one regrouping the endodontically treated or pulpotomy-treated teeth without coronal restoration and the other one regrouping all the other samples, i.e., the untreated teeth (positive controls) and the treated and restored teeth. The strength resistance was lower for the resin simulators than for natural teeth in all groups. Within the limit of this study, strength resistance is not the most important criterion for choosing the type of material, preparation, or endodontic treatment for endocrowns. Resin simulators are not efficient for in vitro strength studies.
- Published
- 2023
- Full Text
- View/download PDF
36. Endometriosis and dyspareunia: Solving the enigma.
- Author
-
Jimenez JCV, Romero LL, Garcia IB, Sanchez ML, and Fernandez RO
- Abstract
Introduction: Endometriosis is a chronic oestrogen-dependent disease that affects 1 in 10 women of childbearing age. Half of these women have deep dyspareunia. The presence of this symptom has been shown to negatively affect your quality of life. There are few studies in the literature that address this issue and its pathophysiology remains poorly understood., Materials and Methods: A case-control study has been carried out in order to assess the multi-causality of dyspareunia in patients with endometriosis. All the patients were assessed in a unit specialising in endometriosis and pelvic pain and their disease was staged using high-resolution ultrasound following the criteria of the IDEA group. The patients were divided into two groups, patients with dyspareunia n = 45 (cases) and those without it n = 55 (controls)., Results: The only element that was statistically significant in explaining the dyspareunia was the presence of nodules in the retrocervical region with p = 0.000. The odds ratio of dyspareunia in the cases group was 5.3 (95 % CI 2.2-12.5)., Conclusions: Dyspareunia in patients with endometriosis is strongly dependent on the presence of nodules in the retrocervical region, although there are other factors involved that remain unknown, so more studies are still needed to understand and optimally address this symptom., Competing Interests: The authors declare that they have no conflicts of interest and nothing to disclose. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. We declare that this article has not been submitted or published previously. All the patients were informed and consented to the elaboration and publication of this review. Similarly, the ethics committee of our centre gave its approval., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
37. Epidemiology of Nonsyndromic, Orofacial Clefts in Texas: Differences by Cleft Type and Presence of Additional Defects.
- Author
-
Navarro Sanchez ML, Swartz MD, Langlois PH, Canfield MA, and Agopian AJ
- Subjects
- Infant, Humans, Texas epidemiology, Retrospective Studies, Prevalence, Cleft Lip epidemiology, Cleft Palate epidemiology
- Abstract
To describe the current epidemiology of nonsyndromic cleft palate alone (CP) and cleft lip with or without cleft palate (CL ± P) in Texas and examine differences in the characteristics of infants with CP and CL ± P based on the presence/absence of additional defects., We used data from the Texas Birth Defects Registry, a statewide active birth defect surveillance system, from 1815 cases with CP and 5066 with CL ± P, without a syndrome diagnosis (1999-2014 deliveries). All live births in Texas were used for comparison. Poisson regression was used to calculate crude and adjusted prevalence ratios (aPR) for each characteristic, separately for each cleft subphenotype., The prevalence of CL ± P and CP in our study was estimated as 8.3 and 3.0 per 10 000 live births, respectively. After adjusting for several characteristics, several factors were associated with CL ± P, CP, or both, including infant sex and maternal race/ethnicity, age, smoking, and diabetes. There were several differences between infants with isolated versus nonisolated clefts. For example, maternal prepregnancy diabetes was associated with an increased prevalence of CL ± P (aPR 7.91, 95% confidence interval [CI]: 5.53, 11.30) and CP (aPR 3.24, 95% CI: 1.43, 7.36), but only when additional defects were present., Findings from this study provide a contemporary description of the distribution of orofacial clefts in Texas accounting for differences between isolated and nonisolated clefts. They may contribute to increasing our understanding of the etiology of CP and CL ± P.
- Published
- 2023
- Full Text
- View/download PDF
38. Preliminary results in tracheal replacement using stented aortic matrices for primary extensive tracheal cancer.
- Author
-
Onorati I, Radu DM, Portela AMS, Peretti M, Guiraudet P, Bardet J, Freynet O, Didier M, Uzunhan Y, Chouahnia K, Duchemann B, Bourinet V, Dutau H, Berthet JP, Marquette CH, Tronc F, Sanchez ML, Trésallet C, Fournier C, Vénissac N, Miyara M, Vicaut E, and Martinod E
- Abstract
Objective: Recent studies have demonstrated the feasibility and favorable long-term results of tracheobronchial replacement using stented cryopreserved aortic allografts. We propose to investigate the outcomes of this emerging technique in the subgroup of patients with extensive tracheal cancer., Methods: This study was based on 13 patients with primary extensive tracheal cancer extracted from the prospective registry TRITON-01 (ClinicalTrials.gov Identifier: NCT04263129), which included 40 patients in total. We analyzed early and late outcomes in this subset of patients., Results: From March 2019 to September 2022, 13 patients were included in the study. There were 9 female and 4 male patients, with a mean age of 53.9 years [36-71 years]. They had tracheal replacement for extended adenoid cystic carcinoma (n = 11), squamous cell carcinoma (n = 1), and mucoepidermoid carcinoma (n = 1). A venovenous extracorporeal membrane oxygenation was used in the 6 last cases. The mean length of resection was 81 mm [50-120 mm]. There was no 30-day postoperative mortality. A complete resection (R0) was achieved in 11 patients. The main late complications consisted of tracheal granulomas related to the stent and requiring repeated bronchoscopies (n = 9), pneumonia (n = 3), airway infection (n = 1), bronchoesophageal fistula (n = 1), mechanical stent obstruction requiring change (n = 2), and mediastinitis treated by antibiotics, drainage, and omentoplasty (n = 1). With a maximal follow-up of 3 years and 7 months, cancer recurrence was observed in 2 patients. All patients were alive at last follow-up except 2 (84.6%)., Conclusions: Airway replacement using stented CAA represents a feasible and promising solution for extensive tracheal cancer., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
39. Physical demands on professional Spanish football referees during matches.
- Author
-
Martínez-Torremocha G, Martin-Sanchez ML, Garcia-Unanue J, Felipe JL, Moreno-Pérez V, Paredes-Hernández V, Gallardo L, and Sanchez-Sanchez J
- Subjects
- Humans, Acceleration, Heart Rate physiology, Football physiology, Running physiology, Soccer physiology
- Abstract
Background: Refereeing is a demanding and intermittent activity that combines high-speed and low-intensity action., Objective: The aim of this study is to analyse the external and internal load of professional Spanish football referees during matches, and to compare the physical demands between halves and between referees in different categories., Methods: The physical demands on 40 professional football referees from the first and second divisions were recorded using global positioning system (GPS) technology and heart rate bands. External load (distance covered, speed, acceleration and deceleration) and internal load (perceived exertion [RPE] and heart rate [HR]) were analysed., Results: The referees in the first division reported lower mean HR and RPE results than those in the second division ( p < 0.05). The total distance covered was similar between the categories ( p > 0.05), but the distance covered at different speed ranges was different ( p < 0.05). Finally, greater reductions in performance between the first and the second halves were found in the second division referees ( p < 0.05)., Conclusions: The results of this study show differences according to the category of referee. This emphasises the need for specific training for professional referees according to their level to ensure optimal performance during matches.
- Published
- 2023
- Full Text
- View/download PDF
40. Nutritional Composition, Phenolic Compounds and Antioxidant Activity of Different Samples of Water Boatmen Eggs (Hemiptera: Corixidae).
- Author
-
Sanchez ML, Caltzontzin V, and Feregrino-Pérez AA
- Abstract
The group of aquatic insects collectively called "water boatmen" or "Axayacatl" (Hemiptera: Corixidae) and their eggs, called "Ahuahutle", have been consumed and cultivated since the pre-Hispanic era in Mexico. Nevertheless, food composition databases contain limited information on the nutritional composition of these eggs. This work evaluates the macronutrients and bioactive compounds of water boatmen eggs obtained from three different locations in Mexico. The primary analyses to be determined for the first time were some bioactive compounds in the eggs, such as phenolic compounds, total flavonoids, condensed tannins content, antioxidant activity (DPPH and ABTS), and, additionally, fatty acids and proximal composition. The results showed that the sample from Hidalgo (AMC) presented the highest number of phenolic compounds (855.12 ± 0.52), followed by ALT (125.52 ± 0.05) and, with the lowest amount, AMT (99.92 ± 0.13), all expressed in an mg GAE/g sample. ALT indicated the highest mol TE/g sample concentration for ABTS (25.34 ± 0.472) and DPPH (39.76 ± 0.054), showing a significant difference in the DPPH method with the AMT samples. The three Corixidae egg samples had between 15 to 18 different fatty acid profiles, and there were statistically significant differences (Student's t -test ≤ 0.05) between the means using MSD. The total fats of the three samples were between 12.5 and 15.5 g/100 g dry basis. In addition, Corixidae eggs are excellent protein sources. Thus, water boatmen's eggs can be considered to be a food rich in bioactive compounds., Competing Interests: The authors declare no conflict of interest.
- Published
- 2022
- Full Text
- View/download PDF
41. Physical demands in Spanish male and female elite football referees during the competition: a prospective observational study.
- Author
-
Martin-Sanchez ML, Oliva-Lozano JM, Garcia-Unanue J, Felipe JL, Moreno-Pérez V, Gallardo L, and Sánchez-Sánchez J
- Subjects
- Female, Humans, Male, Exercise physiology, Athletic Performance physiology, Running physiology, Soccer physiology
- Abstract
Objective: The aim of this study was to analyze the physical demands of elite male and female field referees in match play and compare the physical demands between male and female football referees in the competition., Methods: Match data were collected from 36 elite football referees (19 males and 17 females) during a total of 409 football matches. Electronic performance and tracking systems based on global positioning systems (GPS) were used in this research., Results: Male referees experienced significantly greater physical demands ( p < 0.05) in men league than female referees in women league for total distance, explosive distance, high-intensity breaking distance, total of sprints, sprinting distance, high-speed running distance, high-speed running actions, maximal speed, total of accelerations and decelerations, maximal acceleration and deceleration, acceleration/deceleration., Conclusions: Therefore, strength and conditioning coaches should consider these gender differences in match demands to maximize the fitness-fatigue response of the referees since this may lead to a better performance during the decision-making process in the competition.
- Published
- 2022
- Full Text
- View/download PDF
42. The Fetal Growth Restriction at Term Managed by Angiogenic Factors Versus Feto-Maternal Doppler (GRAFD) Trial to Avoid Adverse Perinatal Outcomes: Protocol for a Multicenter, Open-Label, Randomized Controlled Trial.
- Author
-
Garcia-Manau P, Mendoza M, Bonacina E, Martin-Alonso R, Martin L, Palacios A, Sanchez ML, Lesmes C, Hurtado I, Perez E, Tubau A, Ibañez P, Alcoz M, Valiño N, Moreno E, Borrero C, Garcia E, Lopez-Quesada E, Diaz S, Broullon JR, Teixidor M, Chulilla C, Gil MM, Lopez M, Candela-Hidalgo A, Salinas-Amoros A, Moreno A, Morra F, Vaquerizo O, Soriano B, Fabre M, Gomez-Valencia E, Cuiña A, Alayon N, Sainz JA, Vives A, Esteve E, Ocaña V, López MÁ, Maroto A, and Carreras E
- Abstract
Background: Fetal smallness affects 10% of pregnancies. Small fetuses are at a higher risk of adverse outcomes. Their management using estimated fetal weight and feto-maternal Doppler has a high sensitivity for adverse outcomes; however, more than 60% of fetuses are electively delivered at 37 to 38 weeks. On the other hand, classification using angiogenic factors seems to have a lower false-positive rate. Here, we present a protocol for the Fetal Growth Restriction at Term Managed by Angiogenic Factors Versus Feto-Maternal Doppler (GRAFD) trial, which compares the use of angiogenic factors and Doppler to manage small fetuses at term., Objective: The primary objective is to demonstrate that classification based on angiogenic factors is not inferior to estimated fetal weight and Doppler at detecting fetuses at risk of adverse perinatal outcomes., Methods: This is a multicenter, open-label, randomized controlled trial conducted in 20 hospitals across Spain. A total of 1030 singleton pregnancies with an estimated fetal weight ≤10th percentile at 36+0 to 37+6 weeks+days will be recruited and randomly allocated to either the control or the intervention group. In the control group, standard Doppler-based management will be used. In the intervention group, cases with a soluble fms-like tyrosine kinase to placental growth factor ratio ≥38 will be classified as having fetal growth restriction; otherwise, they will be classified as being small for gestational age. In both arms, the fetal growth restriction group will be delivered at ≥37 weeks and the small for gestational age group at ≥40 weeks. We will assess differences between the groups by calculating the relative risk, the absolute difference between incidences, and their 95% CIs., Results: Recruitment for this study started on September 28, 2020. The study results are expected to be published in peer-reviewed journals and disseminated at international conferences in early 2023., Conclusions: The angiogenic factor-based protocol may reduce the number of pregnancies classified as having fetal growth restriction without worsening perinatal outcomes. Moreover, reducing the number of unnecessary labor inductions would reduce costs and the risks derived from possible iatrogenic complications. Additionally, fewer inductions would lower the rate of early-term neonates, thus improving neonatal outcomes and potentially reducing long-term infant morbidities., Trial Registration: ClinicalTrials.gov NCT04502823; https://clinicaltrials.gov/ct2/show/NCT04502823., International Registered Report Identifier (irrid): DERR1-10.2196/37452., (©Pablo Garcia-Manau, Manel Mendoza, Erika Bonacina, Raquel Martin-Alonso, Lourdes Martin, Ana Palacios, Maria Luisa Sanchez, Cristina Lesmes, Ivan Hurtado, Esther Perez, Albert Tubau, Patricia Ibañez, Marina Alcoz, Nuria Valiño, Elena Moreno, Carlota Borrero, Esperanza Garcia, Eva Lopez-Quesada, Sonia Diaz, Jose Roman Broullon, Mireia Teixidor, Carolina Chulilla, Maria M Gil, Monica Lopez, Amparo Candela-Hidalgo, Andrea Salinas-Amoros, Anna Moreno, Francesca Morra, Oscar Vaquerizo, Beatriz Soriano, Marta Fabre, Elena Gomez-Valencia, Ana Cuiña, Nicolas Alayon, Jose Antonio Sainz, Angels Vives, Esther Esteve, Vanesa Ocaña, Miguel Ángel López, Anna Maroto, Elena Carreras. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 11.10.2022.)
- Published
- 2022
- Full Text
- View/download PDF
43. Impact of the COVID pandemic on vascular access creation for haemodialysis in 16 Spanish haemodialysis centres.
- Author
-
Arenas Jimenez MD, Méndez A, Furaz K, Botella A, Yetman D, Cazar R, Cabana ML, Handel M, Sanchez ML, Delgado M, Vasquez MM, Martinez I, Pereira M, González-Parra E, Pizarro-Sánchez MS, Garayzabal IS, Rodriguez-Osorio L, Portoles J, Hernán D, and Miranda B
- Abstract
Background: The coronavirus disease (COVID) pandemic has resulted in a major disruption in healthcare that has affected several medical and surgical specialties. European and American Vascular Societies have proposed deferring the creation of an elective vascular access (VA) [autologous or prosthetic arteriovenous fistula (AVF) or arteriovenous graft (AVG)] in incident patients on haemodialysis (HD) in the era of the COVID pandemic. The aim of this study is to examine the impact of the COVID pandemic on VA creation and the central venous catheter (CVC)-related hospitalizations and complications in HD patients dialyzed in 16 Spanish HD units of three different regions., Methods: We compared retrospectively two periods of time: the pre-COVID (1 January 2019-11 March 2020) and the COVID era (12 March 2020-30 June 2021) in all HD patients (prevalent and incident) dialyzed in our 16 HD centres. The variables analysed were type of VA (CVC, AVF and AVG) created, percentage of CVC in incident and prevalent HD patients, CVC-related hospitalizations and complications (infection, extrusion, disfunction, catheter removal) and percentage of CVC HD sessions that did not reach the goal of Kt (>45) as a marker of HD adequacy., Results: A total of 1791 VAs for HD were created and 905 patients started HD during the study period. Patients who underwent vascular access surgery during the COVID period compared with pre-COVID period were significantly younger, with a significant decrease in surgical activity to create AVFs and AVGs in older HD patients (>75 and >85 years of age). There was a significant increase in CVC placement (from 59.7% to 69.5%; P < 0.001) from the pre-COVID to the COVID period. During the COVID pandemic, a significantly higher number of patients started HD through a CVC (80.3% versus 69.1%; P < 0.001). The percentage of CVC in prevalent HD patients has not decreased in the 19 months since the start of the pandemic [414 CVC/1058 prevalent patients (39.4%)]. No significant changes were detected in CVC-related hospitalizations between the pre-COVID and COVID periods. In the COVID period, a significant increase in catheter replacement and the percentage of HD session that did not reach the HD dose objective (Kt > 45) was observed., Conclusions: COVID has presented a public health system crisis that has influenced VA for HD, with an increase in CVCs relative to AVFs. A decrease in HD sessions that did not reach the HD dose objective was observed in the COVID period compared with a pre-COVID period., (© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.)
- Published
- 2022
- Full Text
- View/download PDF
44. Birth defect co-occurrence patterns in the Texas Birth Defects Registry.
- Author
-
Benjamin RH, Scheuerle AE, Scott DA, Navarro Sanchez ML, Langlois PH, Canfield MA, Northrup H, Schaaf CP, Ray JW, McLean SD, Chen H, Swartz MD, Lupo PJ, and Agopian AJ
- Subjects
- Anal Canal abnormalities, Esophagus abnormalities, Humans, Infant, Kidney abnormalities, Registries, Spine abnormalities, Texas epidemiology, Trachea abnormalities, Heart Defects, Congenital epidemiology, Limb Deformities, Congenital
- Abstract
Background: The population-level landscape of co-occurring birth defects among infants without a syndromic diagnosis is not well understood., Methods: We analyzed data from 40,771 infants with two or more major birth defects in the Texas Birth Defects Registry (TBDR; 1999-2014). We calculated adjusted observed-to-expected (O/E) ratios for all two, three, four, and five-way combinations of 138 major defects., Results: Among 530 patterns with the highest adjusted O/E ratios (top 5% of 10,595 patterns), 66% included only defects co-occurring within one organ system and 28% were suggestive of known patterns (e.g., midline developmental defects). Of the remaining patterns, the combination of defects with the highest O/E ratio (193.8) encompassed the diaphragm, spine, spleen, and heart defects. Fourteen patterns involved heart and spine defects with or without rib defects. Ten additional patterns primarily involved two hallmark components of VACTERL association (specifically, vertebral defects, anal atresia, cardiac defects, renal, or limb defects, but not tracheoesophageal fistula)., Conclusions: Our analyses provide a description of the birth defect co-occurrence patterns in a multi-ethnic, population-based sample, and revealed several patterns of interest. This work complements prior work that has suggested etiologic connections between select defects (e.g., diaphragmatic hernia and heart and spleen anomalies; heart and spine defects)., Impact: In this large-scale, population-based study of birth defect co-occurrence patterns, we found several birth defect combinations of potential interest that warrant further investigation: congenital diaphragmatic hernia, heart, spine, and spleen defects and scimitar syndrome with vertebral defects. The majority of patterns of co-occurring defects observed more frequently than expected involved multiple defects within the same system and combinations suggestive of known associations. Nearly all of the top patterns (beyond the same system and those suggestive of known associations) involved organ systems that are components of the VACTERL association, with heart, spine, and rib defect patterns being the most common., (© 2021. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
45. Prevalence of critical congenital heart defects and selected co-occurring congenital anomalies, 2014-2018: A U.S. population-based study.
- Author
-
Stallings EB, Isenburg JL, Aggarwal D, Lupo PJ, Oster ME, Shephard H, Liberman RF, Kirby RS, Nestoridi E, Hansen B, Shan X, Navarro Sanchez ML, Boyce A, and Heinke D
- Subjects
- Female, Fetus, Humans, Infant, Live Birth, Pregnancy, Prevalence, Risk Factors, Heart Defects, Congenital complications, Heart Defects, Congenital diagnosis, Heart Defects, Congenital epidemiology
- Abstract
Background: Critical congenital heart defects (CCHDs) are one of the most common types of birth defects and can lead to significant morbidity and mortality along with surgical or catheter interventions within the first year of life. This report updates previously published estimates of CCHD prevalence with the latest population-based surveillance data from 19 birth defect surveillance programs., Methods: The U.S. population-based surveillance programs submitted data on identified cases of 12 CCHDs and co-occurring cardiovascular and chromosomal birth defects from 2014 to 2018. We estimated prevalence by program type and maternal and infant characteristics. Among nine programs with active case ascertainment that collect more than live births, we estimated the percentage of co-occurring cardiovascular and chromosomal birth defects for the 12 CCHDs., Results: We identified 18,587 cases of CCHD among all participating programs. Overall CCHD prevalence was 19.6 per 10,000 live births among all 19 programs and 20.2 per 10,000 live births among active programs. Among maternal racial/ethnic groups, infants/fetuses born to American Indian/Alaska Native mothers showed the highest overall prevalence for all CCHDs (28.3 per 10,000) along with eight of the 12 individual CCHDs. Among 7,726 infants/fetuses with CCHD from active case ascertainment programs, 15.8% had at least one co-occurring chromosomal birth defect., Conclusion: Our study provides prevalence estimates for CCHDs by maternal and infant characteristics along with co-occurrence with cardiovascular and chromosomal birth defects among infants/fetuses with CCHD using one of the largest and most recent cohorts since the implementation of widespread CCHD screening. These data can provide a basis for future research to better understand risk factors for these defects., (© 2022 Wiley Periodicals LLC. This article has been contributed to by US Government employees and their work is in the public domain in the USA.)
- Published
- 2022
- Full Text
- View/download PDF
46. Corrigendum to "Patterns of co-occurring birth defects among infants with hypospadiasˮ [J Pediatr Urol 17 (2021) 64.e1-64.e8].
- Author
-
Ludorf KL, Benjamin RH, Navarro Sanchez ML, McLean SD, Northrup H, Mitchell LE, Langlois PH, Canfield MA, Scheuerle AE, Scott DA, Schaaf CP, Ray JW, Oluwafemi O, Chen H, Swartz MD, Lupo PJ, and Agopian AJ
- Published
- 2021
- Full Text
- View/download PDF
47. Patterns of congenital anomalies among individuals with trisomy 13 in Texas.
- Author
-
Diaz D, Benjamin RH, Navarro Sanchez ML, Mitchell LE, Langlois PH, Canfield MA, Chen H, Scheuerle AE, Schaaf CP, Scott DA, Northrup H, Ray JW, McLean SD, Swartz MD, Ludorf KL, Lupo PJ, and Agopian AJ
- Subjects
- Abnormalities, Multiple epidemiology, Abnormalities, Multiple pathology, Adolescent, Adult, Brain pathology, Child, Child, Preschool, Congenital Abnormalities epidemiology, Congenital Abnormalities genetics, Congenital Abnormalities pathology, Female, Genetic Counseling, Heart Defects, Congenital pathology, Holoprosencephaly pathology, Humans, Infant, Infant, Newborn, Live Birth epidemiology, Live Birth genetics, Male, Pregnancy, Texas, Trisomy 13 Syndrome epidemiology, Trisomy 13 Syndrome pathology, Young Adult, Abnormalities, Multiple genetics, Heart Defects, Congenital genetics, Holoprosencephaly genetics, Trisomy 13 Syndrome genetics
- Abstract
Few population-based studies have analyzed patterns of co-occurring birth defects among those with trisomy 13. We evaluated the frequency of all possible combinations of any one, two, three, or four additional co-occurring birth defects among 736 individuals with trisomy 13 using data from the Texas Birth Defects Registry for deliveries during 1999-2014. We calculated the observed-to-expected ratio for each combination, adjusting for the known tendency for birth defects to cluster non-specifically. To address potential ascertainment differences among live births and non-live births, we repeated analyses specifically among live births. The combination of defects with the largest observed-to-expected ratio was microcephalus, reduction deformities of brain (e.g., holoprosencephaly), anomalies of nose, and polydactyly. As expected, most of the highest 30 observed-to-expected ratios involved combinations with documented features of trisomy 13, including defects of the scalp (e.g., aplasia cutis) and heart. Results were similar among sensitivity analyses restricted to live births. Our findings may help further delineate the phenotypic spectrum for trisomy 13 and may inform future research related to improving screening and counseling for the condition., (© 2021 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
48. Dental Trauma Management in a Young Teenager through Endodontics and Implantology: A Case Report.
- Author
-
Munoz-Sanchez ML, Decerle N, Devoize L, Nicolas E, Cousson PY, and Veyrune JL
- Abstract
Endodontic treatment is often the first-line procedure to manage the immediate or long-term aftermath of dental trauma, particularly in cases of luxation or avulsion. Failure to manage trauma in the short or medium term leads to significant functional or aesthetic consequences, especially in the adolescence period. Under this specific conditions, endodontic treatment could provide a temporary solution by keeping teeth with poor prognosis on the arch while waiting for better anatomical conditions for implantology. This clinical case aimed to describe the management of a maxilla-facial dental trauma and the following consequences in a 10-year-old male patient. Clinical and radiological examination showed complete extrusive luxation of 11 and 21 and intrusive luxation of 12 and 22. Endodontic treatment of 11 and 21 was performed six months after the trauma. Two years later, the patient was referred to the endodontic department because pink spot lesions appeared on 12 and 22 due to cervical invasive resorptions (class III for 12 and class II for 22). Endodontic treatment of 12 and filling with resin composite of 22 were performed. During the following two years, complication management finally led to placement of four OBI
® (Euroteknika, Sallanches, France)-type mini-implants after avulsion of all four maxillary incisors. Palliative endodontic treatment helped maintain the prosthetic space and the volume of supporting tissue needed for future implant placement. The interest of using delaying procedures (palliative endodontic treatments and mini-implants) was to allow the patient to complete growth. Managing early treatment failure of trauma in adolescents has to be pluridisciplinary and should take into account the evaluation of the treatment's difficulty, the prognosis of the endodontic treatment, the available bone volume and the pubertal growth stage.- Published
- 2021
- Full Text
- View/download PDF
49. Radiological Evaluation of Stainless Steel Crowns Placed on Permanent Teeth in Patients Treated under General Anaesthesia.
- Author
-
Munoz-Sanchez ML, Linas N, Decerle N, Collado V, Faulks D, Nicolas E, Hennequin M, and Cousson PY
- Subjects
- Anesthesia, General, Crowns, Dental Restoration, Permanent, Humans, Retrospective Studies, Stainless Steel, Tooth, Deciduous
- Abstract
Evidence-based evaluations of dental treatment are needed to support the development of special care dentistry services. This retrospective study was designed to collect and analyse X-ray images of permanent teeth restored with stainless steel crowns (SSC) in patients treated under general anaesthesia. Between 2013 and 2019, 360 permanent molars were crowned with SSCs in 198 adult patients. One calibrated investigator used an original validated tool to evaluate four radiographic criteria for molars restored with SSCs: (i) marginal adaptation; (ii) interdental proximal contact; (iii) the presence of glass ionomer cement overflow; and (iv) the loss of alveolar bone. Overall, no defect or a minor defect was reported for the majority of SSCs for the criteria "Marginal adaptation" (62.5%, n = 320), "Proximal contact" (82.2%, n = 236) and "Cement overflow" (95.8%, n = 337). Alveolar bone resorption was reported in 8.3% of cases, n = 14, after a mean period of 8.9 ± 14.3 months. It was shown that the restoration of permanent teeth using SSCs placed under general anaesthesia presents a low risk of periodontal morbidity in the medium term when assessed radiographically.
- Published
- 2021
- Full Text
- View/download PDF
50. Patterns of co-occurring birth defects among infants with hypospadias.
- Author
-
Ludorf KL, Benjamin RH, Navarro Sanchez ML, McLean SD, Northrup H, Mitchell LE, Langlois PH, Canfield MA, Scheuerle AE, Scott DA, Schaaf CP, Ray JW, Oluwafemi O, Chen H, Swartz MD, Lupo PJ, and Agopian AJ
- Subjects
- Genitalia, Male, Humans, Infant, Male, Prevalence, Registries, Texas epidemiology, United States epidemiology, Congenital Abnormalities epidemiology, Hypospadias epidemiology
- Abstract
Introduction: Hypospadias, one of the most common male genital birth defects, occurs in 1 out of every 200 male births in the United States and is increasing in prevalence globally., Objective: This study aimed to characterize the combinations of birth defects that co-occur with hypospadias more often than expected by chance, while accounting for the complex clustering patterns of congenital defects., Study Design: We analyzed cases with hypospadias and at least one additional co-occurring defect from the Texas Birth Defect Registry born between 1999 and 2014. For each combination, we calculated adjusted observed-to-expected (O/E) ratios, using Co-Occurring Defect Analysis (CODA)., Results: Among 16,442 cases with hypospadias and without known syndromes, 2,084 (12.7%) had at least one additional defect. Many of the birth defect combinations within the highest adjusted O/E ratios included cardiac, musculoskeletal, and additional urogenital defects. For example, a top combination with an adjusted O/E of 139.0 included renal agenesis and dysgenesis, reduction defects of the upper limb, and other anomalies of upper limb (including shoulder girdle). High adjusted O/E ratios were also observed in combinations that included defects outside of the urogenital developmental field. For instance, the combination with the highest O/E ratio included buphthalmos, and congenital cataract and lens anomalies (adjusted O/E ratio: 192.9). Similar results were obtained when we restricted our analyses to cases with second- or third-degree hypospadias., Discussion: Many combinations in the top results were expected (e.g., multiple urogenital defects); however, some combinations with seemingly unrelated patterns of defects may suggest the presence of some etiologic mechanisms yet to be identified., Conclusion: In summary, this study described patterns of co-occurring defect combinations with hypospadias that can inform further study and may provide insights for screening and diagnostic practices., Competing Interests: Conflict of interest None., (Copyright © 2020 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.